chronic
obstruct
pulmonari
diseas
copd
major
incur
global
health
burden
current
largest
caus
death
world
importantli
much
diseas
burden
health
care
utilis
copd
associ
manag
comorbid
eg
skelet
muscl
wast
ischem
heart
diseas
cognit
dysfunct
infect
viral
bacteri
acut
exacerb
aecopd
current
pharmacolog
treatment
copd
rel
ineffect
develop
effect
therapi
sever
hamper
lack
understand
mechan
mediat
underli
copd
sinc
comorbid
tremend
impact
prognosi
sever
copd
american
thorac
societyeuropean
respiratori
societi
atser
research
statement
copd
urgent
call
studi
elucid
pathobiolog
mechan
link
copd
comorbid
emerg
copd
patient
metabol
syndrom
met
comorbid
current
clear
whether
metabol
syndrom
independ
coexist
condit
direct
consequ
progress
lung
patholog
copd
patient
met
import
clinic
implic
copd
outcom
identif
diseas
mechan
link
copd
met
key
effect
therapi
comprehens
review
discuss
potenti
mechan
link
met
copd
henc
plausibl
therapeut
strategi
treat
debilit
comorbid
copd
chronic
obstruct
pulmonari
diseas
copd
major
incur
global
health
burden
current
largest
caus
death
world
importantli
much
diseas
burden
health
care
utilis
copd
associ
manag
comorbid
eg
skelet
muscl
wast
ischem
heart
diseas
cognit
dysfunct
infect
viral
bacteri
acut
exacerb
aecopd
current
pharmacolog
treatment
copd
rel
ineffect
develop
effect
therapi
sever
hamper
lack
understand
mechan
mediat
underli
copd
sinc
comorbid
tremend
impact
prognosi
sever
copd
american
thorac
societyeuropean
respiratori
societi
atser
research
statement
copd
urgent
call
studi
elucid
pathobiolog
mechan
link
copd
comorbid
emerg
copd
patient
metabol
syndrom
met
comorbid
current
clear
whether
metabol
syndrom
independ
coexist
condit
direct
consequ
progress
lung
patholog
copd
patient
met
import
clinic
implic
copd
outcom
identif
diseas
mechan
link
copd
met
key
effect
therapi
comprehens
review
discuss
potenti
mechan
link
met
copd
henc
plausibl
therapeut
strategi
treat
debilit
comorbid
copd
chronic
obstruct
pulmonari
diseas
copd
major
incur
global
health
burden
current
largest
caus
death
world
vogelmei
et
al
copd
incur
total
billion
econom
cost
us
commun
guarascio
ray
finch
self
importantli
much
diseas
burden
health
care
utilis
copd
associ
manag
comorbid
eg
skelet
muscl
wast
ischem
heart
diseas
cognit
dysfunct
infecti
viral
bacteri
acut
exacerb
aecopd
vogelmei
et
al
mani
patient
copd
also
present
metabol
syndrom
met
cluster
condit
includ
diabet
prediabet
insulin
resist
abdomin
obes
high
cholesterol
high
blood
pressur
estim
quarter
world
adult
popul
metabol
syndrom
intern
diabet
feder
twice
like
die
three
time
like
heart
attack
stroke
compar
peopl
without
syndrom
alberti
et
al
morbid
motil
rate
amplifi
met
coupl
copd
alberti
et
al
sin
man
review
discuss
mechan
crosstalk
clinic
signific
therapeut
strategi
copd
met
copd
diseas
characteris
persist
respiratori
symptom
poorlyrevers
airflow
limit
usual
progress
airflow
limit
associ
chronic
inflammatori
respons
airway
lung
noxiou
particl
gase
cigarett
smoke
major
caus
copd
account
case
develop
countri
vogelmei
et
al
copd
encompass
larg
airway
bronchiti
mucu
plug
chronic
obstruct
bronchiol
fibrosi
obstruct
small
airway
emphysema
enlarg
airspac
destruct
lung
parenchyma
loss
lung
elast
closur
small
airway
mani
patient
copd
three
patholog
condit
ie
bronchiti
chronic
obstruct
bronchiol
emphysema
rel
extent
emphysema
obstruct
bronchiol
overal
diseas
manifest
vari
within
individu
patient
airflow
limit
diagnos
use
spirometri
accord
global
initi
chronic
obstruct
lung
diseas
gold
world
health
organ
criteria
base
calcul
forc
expiratori
volum
one
second
fev
sever
copd
classifi
four
stage
gold
respect
deterior
lung
function
symptom
global
strategi
diagnosi
manag
prevent
copd
report
abcd
gold
assess
tool
combin
spirometri
patient
symptom
assess
use
modifi
british
medic
research
council
mmrc
questionnair
copd
assess
test
score
cat
histori
exacerb
facilit
therapeut
strategi
individu
patient
level
vogelmei
et
al
global
strategi
diagnosi
manag
prevent
copd
report
altern
assess
bode
index
bodi
mass
index
airflow
obstruct
dyspnoea
exercis
capac
index
copd
propos
may
offer
comprehens
measur
sever
also
take
account
system
manifest
reflect
fev
celli
et
al
patient
copd
develop
myriad
symptom
cough
sputum
product
progress
exert
breathless
diseas
progress
patient
intermedi
gold
diseas
stage
beyond
tend
experi
frequent
sever
worsen
respiratori
symptom
ie
exacerb
larg
attribut
bacteri
viral
chest
infect
well
pollut
barn
celli
exacerb
constitut
major
cost
patient
care
also
greatli
increas
rate
mortal
morbid
past
decad
grow
bodi
evid
suggest
copd
system
diseas
patholog
manifest
restrict
pulmonari
inflamm
airway
remodel
barn
barn
celli
decram
et
al
fact
major
patient
copd
die
nonrespiratori
disord
make
comorbid
copd
mcgarvey
et
al
best
recogn
system
manifest
copd
includ
system
inflamm
cardiovascular
diseas
cvd
muscl
wast
dysfunct
osteoporosi
anaemia
clinic
depress
anxieti
barn
celli
wouter
importantli
increas
evid
suggest
metabol
syndrom
met
critic
clinic
compon
associ
copd
one
featur
met
obes
diabet
frequent
found
individu
admit
hospitalis
crisa
et
al
fabbri
luppi
begh
rabe
cigarett
smoke
major
risk
factor
copd
vogelmei
et
al
one
import
risk
factor
chronic
diseas
copdassoci
comorbid
fabbri
rabe
report
caus
copd
includ
occup
factor
eg
miner
worker
textil
industri
respiratori
infect
atmospher
pollut
passiv
smoke
salvi
barn
repeat
exposur
irrit
promot
local
inflamm
airway
lead
obstruct
reduct
fev
complet
revers
even
bronchodil
treatment
qureshi
sharafkhaneh
hanania
unresolv
chronic
inflamm
airway
may
amplifi
give
rise
sever
condit
limit
airflow
chronic
bronchiti
condit
character
inflamm
bronchial
wall
associ
hyperplasia
goblet
cell
enlarg
tracheobronch
submucosa
mucu
hypersecret
lahouss
et
al
develop
emphysema
due
destruct
wall
termin
bronchiol
driven
imbalanc
proteas
antiproteas
lung
cigarett
smoke
abboud
vimalanathan
kersul
et
al
bronchiol
anoth
lung
patholog
may
develop
small
airway
lung
becom
perman
damag
persist
inflam
repeat
exposur
cigarett
smoke
irrit
fume
diseas
progress
varieti
cell
type
includ
macrophag
neutrophil
tcell
becom
hyperactiv
releas
proinflammatori
mediat
includ
tumour
necrosi
monocyt
chemotact
reactiv
oxygen
speci
ro
neutrophil
chemotact
factor
leukotrien
b
ltb
respons
irrit
particular
cigarett
smoke
vlaho
bozinovski
mediat
serv
perpetu
inflammatori
respons
recruit
peripher
blood
monocyt
neutrophil
cytotox
tcell
airway
recruit
cell
particularli
activ
macrophag
neutrophil
releas
proteas
result
tissu
destruct
emphysema
barn
fabbri
rabe
simultan
ro
gener
macrophag
constitut
oxid
insult
caus
lung
inflamm
tissu
injuri
copd
patient
also
suscept
viral
bacteri
infect
amplifi
lung
inflamm
ro
product
caus
rapid
declin
lung
function
repeat
episod
acut
exacerb
copd
aecopd
barn
celli
decram
et
al
recent
genomewid
associ
studi
also
identifi
genet
predisposit
particular
antitrypsin
defici
import
factor
develop
copd
ding
et
al
jiang
et
al
siedlinski
et
al
clear
heterogen
clinic
manifest
copd
greatli
attribut
environment
genet
cue
exampl
small
airway
limit
commonli
found
copd
patient
cigarett
smoke
histori
wherea
nonsmok
mainli
develop
emphysemadomin
phenotyp
character
increas
alveolar
space
destruct
burgel
et
al
castaldi
et
al
factor
might
impact
diseas
present
progress
includ
age
gender
preexist
condit
eg
asthma
ethnic
well
establish
lung
function
declin
increas
age
fletcher
peto
moreov
femal
copd
patient
tend
suscept
toxic
effect
cigarett
smoke
han
et
al
asthma
appear
major
underli
risk
factor
copd
evidenc
find
copd
patient
asthmat
soriano
et
al
rapid
declin
lung
function
observ
smoker
asthma
without
lang
parner
vestbo
schnohr
jensen
final
popul
group
poorer
socialeconom
statu
tend
greater
risk
develop
copd
complic
wealthier
counterpart
fragoso
lawlor
ebrahim
davey
smith
sahni
talwar
khanijo
talwar
shohaimi
et
al
like
relat
poor
nutrit
statu
live
standard
exposur
pollut
high
smoke
rate
along
poor
access
health
care
cardiovascular
diseas
cvd
skelet
muscl
wast
metabol
abnorm
classic
comorbid
found
copd
patient
austin
crack
bozinovski
miller
vlaho
vogelmei
et
al
coexist
condit
contribut
ill
health
also
greatli
increas
risk
mortal
stage
copd
well
incid
hospitalis
franssen
rochest
hypertens
peripher
vascular
diseas
like
frequent
occur
cvdrelat
comorbid
copd
affect
patient
divo
et
al
progress
diseas
copd
patient
increas
risk
develop
arrhythmia
ischem
myocardi
damag
even
heart
failur
bhatt
dransfield
henc
impair
fev
demonstr
power
predictor
cardiovascular
mortal
young
hopkin
eaton
meanwhil
sever
airflow
obstruct
report
promot
arteri
stiff
sabit
et
al
turn
exacerb
cardiovascularrel
comorbid
copd
skelet
muscl
wast
dysfunct
anoth
common
condit
associ
copd
sever
impact
patient
qualiti
life
surviv
passey
et
al
loss
muscl
mass
found
copd
patient
preval
well
extent
wast
worsen
patient
advanc
copd
schol
broekhuizen
welingscheep
wouter
sergi
et
al
vestbo
et
al
skelet
muscl
wast
power
predictor
mortal
copd
independ
lung
function
impair
schol
slangen
volov
wouter
patient
sever
copd
reduc
midthigh
crosssect
area
less
approxim
higher
odd
ratio
mortal
patient
similar
degre
airflow
limit
preserv
muscl
size
marqui
et
al
low
fat
free
mass
index
ffmi
reduc
quadricep
strength
identifi
predictor
copd
mortal
independ
lung
function
declin
schol
swallow
et
al
highlight
import
muscl
mass
function
overal
patholog
copd
clinic
rapid
deterior
lean
muscl
mass
describ
follow
acut
exacerb
caus
loss
strength
endur
allair
et
al
gosker
et
al
addit
loss
muscl
mass
strength
phenotyp
chang
occur
muscl
copd
patient
shift
fibr
type
observ
increas
proport
fast
glycolyt
type
ii
fibr
reduct
slow
oxid
type
fibr
debigar
cote
hould
leblanc
maltai
jobin
et
al
vogiatzi
et
al
whittom
et
al
lung
patholog
copd
larg
irrevers
inher
adapt
muscl
tissu
offer
therapeut
opportun
tackl
muscl
wast
potenti
revers
delay
progress
aspect
diseas
improv
patient
qualiti
life
patient
copd
often
one
physiolog
abnorm
featur
metabol
syndrom
cebron
lipovec
et
al
obes
emerg
import
featur
met
found
earli
stage
copd
gold
ten
hacken
abdomin
obes
found
reliabl
predictor
lung
function
impair
leon
et
al
importantli
presenc
met
impos
limit
exercis
capac
could
turn
hamper
lung
function
gener
wellb
copd
patient
predispos
sever
comorbid
andor
clinic
complic
lung
cancer
hartman
boezen
de
greef
bossenbroek
ten
hacken
met
complex
disord
recognis
clinic
presenc
cluster
risk
factor
includ
excess
abdomin
obes
bodi
mass
index
bmi
kgm
elev
blood
pressur
proatherogen
blood
lipid
profil
impair
fast
blood
glucos
without
insulin
resist
alberti
et
al
saltiel
olefski
metabol
risk
factor
associ
one
anoth
togeth
risk
factor
promot
atherosclerosi
hutcheson
rocic
accord
intern
diabet
feder
idf
gener
consensu
neither
cigarett
smoke
copd
canon
risk
factor
met
vice
versa
clear
mechanist
data
causal
relationship
howev
recent
clinic
find
suggest
strong
associ
copd
met
firstli
met
found
twice
common
copd
patient
compar
gener
popul
sever
studi
demonstr
preval
see
tabl
notabl
almost
patient
copd
manifest
one
compon
met
marqui
et
al
met
confer
increas
risk
type
diabet
mellitu
doubl
risk
develop
cvd
next
year
alberti
et
al
moreov
met
increas
risk
stroke
risk
myocardi
infarct
doubl
risk
mortal
compar
without
syndrom
alberti
et
al
copd
met
coexist
occurr
comorbid
complic
amplifi
sin
man
copd
patient
met
present
sever
form
diseas
reflect
dyspnoea
lower
fev
requir
medic
eg
inhal
glucocorticoid
control
diseas
diezmanglano
barqueroromero
almagro
et
al
preval
met
comorbid
origin
thought
associ
copd
sever
age
hildrum
mykletun
hole
midthjel
dahl
howev
recent
data
demonstr
met
present
larg
proport
copd
patient
younger
age
group
less
sever
form
copd
mina
et
al
copd
patient
met
greater
insulin
resist
favour
develop
mina
et
al
current
exact
caus
met
copd
patient
remain
poorli
understood
trigger
urgent
call
american
thorac
societi
european
respiratori
societi
studi
elucid
pathobiolog
mechan
link
copd
comorbid
celli
et
al
develop
met
copd
multifactori
origin
share
sever
common
contribut
factor
includ
oxid
stress
inflammatori
cytokin
physic
inact
clini
crisa
rada
malerba
fig
compel
evid
increas
oxid
stress
copd
spill
lung
inflamm
system
circul
play
import
role
pathophysiolog
copd
comorbid
met
barn
celli
bernardo
bozinovski
vlaho
lung
inflamm
copd
lead
rise
number
biomark
associ
neutrophil
inflamm
elastas
calprotectin
bronchoalveolar
lavag
neutrophil
proinflammatori
cytokin
creactiv
protein
crp
peripher
blood
ropck
et
al
chronic
elev
inflammatori
molecul
circul
constitut
lowgrad
system
inflamm
key
mediat
met
exampl
crp
promot
wholebodi
insulin
resist
central
featur
met
de
luca
olefski
moreov
continu
system
inflamm
promot
format
atherosclerot
plaqu
give
rise
cardiovascular
comorbid
copd
patient
fabbri
et
al
mizuno
jacob
mason
adipos
tissu
inflamm
propos
anoth
import
mechan
link
copd
met
obes
copd
patient
expans
adipos
tissu
lead
adipocyt
hypertrophi
hyperplasia
larg
adipocyt
outstrip
local
oxygen
suppli
lead
cell
autonom
hypoxia
activ
local
inflamm
within
adipos
tissu
clini
et
al
diezmanglano
barqueroromero
almagro
et
al
strikingli
sever
marker
inflamm
crp
elev
copd
obes
coexist
rana
et
al
suggest
adipos
tissu
may
anoth
major
contributor
inflamm
copd
preval
obes
copd
patient
first
report
steuten
creutzberg
vrijhoef
wouter
netherland
popul
highest
preval
subject
mild
moder
copd
gold
stage
lowest
eisner
et
al
multiethn
cohort
patient
found
copd
patient
found
also
suffer
obes
defin
bmi
greater
kgm
patient
copd
obes
gener
associ
increas
risk
mortal
howev
surprisingli
number
studi
demonstr
overweight
obes
may
confer
surviv
advantag
leaner
phenotyp
bonsaksen
fagermoen
lerdal
cebron
lipovec
et
al
maatman
et
al
fact
copd
patient
lower
bmi
tend
higher
mortal
rate
compar
patient
normal
bmi
subject
overweight
obes
lower
risk
mortal
cao
et
al
constitut
obes
paradox
howev
import
view
paradox
refer
progress
copd
major
patient
suffer
lung
disord
progress
loss
muscl
mass
vestbo
et
al
like
result
physic
inact
bmi
simpl
indic
weight
height
differenti
lean
muscl
mass
metabol
function
activ
fat
mass
therefor
bmi
mislead
indic
surviv
health
outcom
copd
patient
note
studi
marqui
et
al
demonstr
increas
mortal
risk
copd
patient
low
midthigh
crosssect
area
indic
loss
lean
muscl
mass
line
subsequ
studi
schol
et
al
patient
moderatetosever
copd
also
confirm
lean
mass
serv
independ
predictor
mortal
irrespect
fat
mass
muscl
import
tissu
mechan
contract
produc
movement
also
activ
metabol
tissu
respons
energi
storag
util
moreov
muscl
capabl
secret
system
factor
ie
myokin
act
distal
target
tissu
includ
lung
disrupt
tissu
crosstalk
result
muscl
wast
postul
neg
impact
lung
function
cheung
joham
mark
teed
zhi
xin
ying
guohong
shuy
given
capac
physic
activ
directli
relat
amount
lean
muscl
mass
increas
fat
mass
known
neg
impact
respiratori
mechan
lung
volum
delorey
wyrick
babb
hedenstierna
santesson
pelosi
croci
ravagnan
vicardi
gattinoni
possibl
protect
effect
obes
may
come
lean
muscl
mass
highlight
import
bodi
composit
assess
clinic
manag
copd
patient
concomit
increas
fat
mass
loss
muscl
mass
repres
two
arm
metabol
abnorm
may
relat
system
inflamm
tkacova
system
inflamm
hallmark
copd
also
key
mechan
respons
diseas
repeat
cigarett
smoke
andor
exposur
noxiou
particl
eg
occup
dust
air
pollut
biomass
combust
evok
inflammatori
respons
increas
macrophag
neutrophil
infiltr
lung
meanwhil
oxid
may
also
enter
pulmonari
compart
via
direct
inhal
cigarett
smoke
noxiou
particl
combin
endogen
inhal
oxid
caus
oxid
damag
dna
lipid
carbohydr
protein
therebi
mediat
array
downstream
process
contribut
develop
progress
copd
oxid
damag
activ
resid
cell
lung
eg
epitheli
cell
alveolar
macrophag
gener
chemotact
molecul
recruit
addit
inflammatori
cell
perpetu
oxid
stress
lung
collect
event
lead
viciou
cycl
persist
inflamm
accompani
chronic
oxid
stress
lead
disturb
proteaseantiproteas
balanc
defect
tissu
repair
mechan
acceler
apoptosi
tissu
destruct
result
spill
proinflammatori
mediat
system
circul
system
inflamm
promot
manifest
cardiovascular
diseas
metabol
abnorm
extrapulmonari
comorbid
interconnect
natur
impair
pulmonari
function
decreas
oxygenexchang
effici
turn
would
trigger
hypoxemia
limit
physic
activ
hypoxemia
physic
inact
per
se
capabl
directli
indirectli
promot
develop
metabol
syndrom
comorbid
progress
consequenti
increas
rate
comorbid
wouter
two
main
sourc
proinflammatori
mediat
consid
import
system
inflamm
seen
copd
lung
peripher
organ
particular
adipos
tissu
akpinar
akpinar
ertek
sayin
gulhan
magnussen
watz
sin
man
tkacova
copd
increasingli
recogn
complex
system
diseas
rather
sole
airway
lung
diseas
sourc
system
inflamm
copd
patient
subject
intens
discuss
chung
adcock
kim
roger
criner
vogelmei
et
al
critic
point
discuss
whether
system
inflamm
due
spill
inflamm
aris
predominantli
lung
regul
product
inflammatori
mediat
nonpulmonari
tissu
well
support
spill
concept
studi
demonstr
cigarett
smoke
copd
associ
increas
permeabl
pulmonari
vessel
leaki
contribut
directli
spill
local
proinflammatori
mediat
lung
system
compart
human
bronchial
epithelium
olivera
et
al
olivera
bogg
beenhouw
aden
knall
demonstr
transient
loss
epitheli
barrier
function
upon
exposur
cigarett
smoke
result
macromolecular
permeabl
murin
model
lung
injuri
similar
loss
epitheli
barrier
function
observ
result
increas
leak
surfact
protein
lung
specif
protein
fujita
et
al
well
proinflammatori
cytokin
tamagawa
et
al
circul
favour
develop
system
inflamm
human
increas
alveolarcapillari
membran
permeabl
observ
cigarett
smoke
compar
nonsmok
kennedi
elwood
wigg
pare
hogg
improv
fev
steroid
therapi
associ
restor
alveolarcapillari
membran
permeabl
chou
chen
chuang
kao
huang
well
reduct
system
surfact
protein
level
copd
patient
antoniu
man
et
al
glanc
find
studi
suggest
pulmonari
inflamm
prevail
mechan
system
inflamm
copd
howev
upon
closer
examin
invers
relationship
fev
pulmonari
vessel
permeabl
demonstr
studi
also
indic
lungtocircul
spill
proinflammatori
mediat
may
promin
patient
earli
stage
copd
prior
onset
sever
pulmonari
dysfunct
inde
coexist
obes
metabol
syndrom
demonstr
posit
correl
increas
system
inflamm
well
reduc
physic
activ
independ
lung
function
impair
watz
et
al
meanwhil
declin
pulmonari
function
copd
limit
physic
activ
increas
propens
weight
gain
exacerb
obes
make
matter
wors
excess
obes
acceler
pulmonari
function
loss
togeth
pose
restrict
physic
activ
franssen
odonnel
goossen
blaak
schol
form
viciou
cycl
cigarett
smoke
known
caus
increas
circul
level
low
densiti
lipoprotein
vldl
low
densiti
lipoprotein
ldl
triglycerid
low
level
high
densiti
lipoprotein
hdl
craig
palomaki
haddow
alter
panel
circulatori
factor
gener
believ
proatherosclerot
studi
dyslipidaemia
copd
limit
lipid
profil
yet
well
character
copd
studi
conduct
spanish
popul
involv
subject
found
dyslipidaemia
copd
patient
variou
stage
diseas
de
lucasramo
et
al
recent
studi
report
detect
elev
level
oxidis
ldl
current
smoker
wada
et
al
level
oxidis
ldl
rapidli
reduc
upon
smoke
cessat
komiyama
et
al
lipoprotein
particl
like
vldl
ldl
prone
oxid
modif
inhibit
hdl
healthi
state
oxidis
ldl
predomin
site
atherosclerot
lesion
level
oxidis
ldl
blood
reflect
activ
foam
cell
atherosclerot
lesion
mashiba
et
al
one
hand
alter
circulatori
profil
copd
patient
render
ldl
easili
oxid
hand
number
step
revers
cholesterol
transport
pathway
found
impair
system
inflamm
athyro
katsiki
douma
karagianni
mikhailidi
goldklang
et
al
interest
treatment
underli
diseas
lead
reduct
inflamm
result
return
lipid
profil
toward
normal
dessi
et
al
indic
dyslipidaemia
might
key
mediat
comorbid
stem
system
inflamm
anoth
import
aspect
dyslipidaemia
lie
proinflammatori
properti
certain
lipid
speci
first
elev
level
circul
nonesterifi
lipid
nefa
demonstr
promot
inflamm
gordon
johnson
milner
makowski
kost
et
al
like
triglycerid
nefa
transport
liver
circul
form
lipoprotein
uptak
lipidrich
vldl
ldl
particl
macrophag
lead
lipid
deposit
trigger
cascad
intracellular
signal
mediat
mitogen
activ
protein
kinas
mapk
jnk
result
product
inflammatori
protein
saraswathi
hasti
line
vldl
shown
trigger
proinflammatori
respons
vascular
endotheli
cell
dichtl
et
al
evid
suggest
apart
spill
proinflammatori
mediat
lung
system
inflamm
may
also
aris
dyslipidaemia
support
diet
rich
cholesterol
fat
demonstr
promot
pulmonari
inflamm
tilton
et
al
emphysema
develop
goldklang
et
al
cigarett
smoke
exposur
also
known
impact
key
organ
includ
liver
muscl
white
brown
adipos
tissu
import
lipid
lipoprotein
metabol
hutcheson
rocic
henc
dyslipidaemia
aris
met
cigarett
smoke
may
serv
import
mechanist
link
copd
also
comorbid
nonalcohol
fatti
liver
diseas
nafld
recogn
hepat
manifest
met
fargion
porzio
fracanzani
nafld
collect
term
encompass
nonalcohol
hepat
steatosi
modest
lipid
accumul
within
liver
nonalcohol
steatohepat
nash
often
preced
liver
fibrosi
cirrhosi
hepatocellular
carcinoma
fargion
et
al
nafld
also
identifi
independ
risk
factor
atherosclerosi
cvd
hamaguchi
et
al
targher
et
al
date
molecular
mechan
underli
convers
modest
fatti
liver
nash
remain
poorli
understood
howev
experiment
evid
indic
cigarett
smoke
may
major
risk
factor
patholog
convers
firstli
increas
serum
cholesterol
lipid
level
aris
cigarett
smoke
shown
risk
factor
liver
diseas
corey
cohen
mizou
ueda
hino
yoshimura
elev
serum
lipid
greater
normal
level
divid
line
simpl
steatosi
sever
form
nafld
tannapfel
et
al
secondli
cigarett
smoke
shown
exacerb
hepatocellular
lipid
accumul
laboratori
rodent
cell
cultur
modul
activ
adenosin
monophosphateactiv
protein
kinas
ampk
sterol
respons
element
bind
yuan
shyy
martinsgreen
ampk
master
regul
energi
metabol
basichelixloophelixleucin
zipper
transcript
factor
respons
transcript
activ
lipogen
gene
postic
girard
activ
ampk
inhibit
therebi
block
energyconsum
biosynthet
pathway
lipogenesi
activ
energyproduc
catabol
pathway
fatti
acid
oxid
long
zierath
exposur
cigarett
smoke
rapidli
inhibit
ampk
phosphoryl
function
lead
activ
lipogenesi
driven
yuan
et
al
thirdli
cigarett
smoke
exposur
also
demonstr
perturb
cellular
prooxid
antioxid
balanc
give
rise
oxid
stress
data
laboratori
show
increas
oxid
stress
respons
cigarett
smoke
duong
et
al
liver
cigarett
smoke
stimul
product
hepatocellular
ro
induc
dna
damag
chen
et
al
liver
injuri
worsen
sever
nafld
set
obes
azzalini
et
al
addit
induc
oxid
stress
cigarett
smoke
may
contain
high
level
chemic
toxin
could
profound
effect
nafld
link
format
hepatocellular
carcinoma
exampl
benzopyren
shown
caus
oxid
stress
apoptot
cell
death
primari
rat
hepatocyt
collin
et
al
aldehyd
found
cigarett
smoke
shown
increas
histon
phosphoryl
via
hyperactiv
prolif
pathway
includ
kinas
protein
kinas
b
pkbakt
ibuki
toyooka
zhao
yoshida
mapk
pathway
lee
shukla
histon
modif
import
mechan
chromatin
remodel
regul
gene
express
histon
phosphoryl
report
promot
malign
transform
cancer
develop
choi
et
al
obes
mous
model
nicotin
addit
effect
sever
hepat
steatosi
induc
high
fat
feed
friedman
et
al
liver
tissu
mice
greater
lipid
deposit
level
oxid
stress
incid
hepatocellular
apoptosi
fed
high
fat
diet
alon
may
attribut
neg
impact
nicotin
ampk
activ
friedman
et
al
collect
find
suggest
cigarett
smoke
capabl
caus
liver
injuri
drive
excess
oxid
stress
dysregul
lipid
metabol
hyperactiv
growth
signal
may
serv
import
trigger
patholog
convers
fatti
liver
nash
despit
consist
clinic
relev
experiment
find
controversi
random
placebocontrol
trial
conduct
cohort
israel
report
signific
relationship
cigarett
smoke
liver
function
sofer
boaz
mata
mashavi
shargorodski
moreov
post
hoc
analysi
greek
atorvastatin
coronari
heart
diseas
evalu
greac
studi
also
reveal
associ
cigarett
smoke
nafld
athyro
tziomalo
et
al
paradox
crosssect
studi
involv
particip
demonstr
passiv
smoke
activ
smoke
posit
correl
preval
nafld
middleag
elderli
popul
liu
et
al
appar
controversi
like
explain
number
concurr
factor
obes
smoke
histori
gender
age
genet
predisposit
henc
factor
taken
consider
futur
clinic
studi
interest
cigarett
smoke
report
acceler
nafld
patholog
liver
injuri
obes
present
azzalini
et
al
suggest
deleteri
effect
cs
liver
may
requir
addit
metabol
insult
strengthen
connect
cigarett
smoke
metabol
derang
copd
although
exact
preval
vari
studi
bitar
ghoto
dayo
arain
parveen
makarevich
valevich
pochtavtsev
parappil
depczynski
collett
mark
patient
copd
gener
tend
greater
chanc
develop
diabet
type
preval
copd
patient
versu
gener
popul
cazzola
bettoncelli
sessa
cricelli
biscion
yin
et
al
persist
system
inflamm
appear
import
mechanist
factor
respons
progress
two
diseas
akpinar
et
al
tkacova
yanbaeva
denten
creutzberg
wouter
greatli
increas
individu
risk
comorbid
cardiovascular
complic
barn
celli
cazzola
et
al
vogelmei
et
al
noteworthi
mutual
relationship
exist
two
diseas
patient
copd
risk
develop
diabet
copd
also
found
common
comorbid
diabet
cazzola
et
al
first
cigarett
smoke
doubl
risk
develop
diabet
like
attribut
worsen
insulin
resist
driven
system
inflamm
andor
oxid
stress
cigarett
smoke
oh
sin
moreov
risk
develop
diabet
increas
overweightobes
subject
cravo
esquina
lambert
et
al
secondli
experiment
evid
demonstr
airway
inflamm
blunt
metabol
action
insulin
liver
supress
glucos
product
peripher
tissu
glucos
uptak
muscl
adipos
tissu
lead
impair
glucos
metabol
cyphert
et
al
importantli
blunt
insulin
action
tissu
occur
without
detect
defect
insulin
receptor
signal
line
inflamm
airway
epithelium
shown
neg
regul
glucos
metabol
via
limit
muscl
blood
flow
microvascular
recruit
without
impair
insulin
signal
clerk
et
al
thirdli
use
corticosteroid
therapi
copd
report
associ
increas
blood
glucos
level
barn
associ
appear
dosedepend
price
et
al
howev
controversi
exist
regard
advers
effect
corticosteroid
therapi
diabet
sever
studi
report
evid
associ
dendukuri
blai
lelori
flynn
macdonald
hapca
mackenzi
schembri
obyrn
et
al
contrari
impair
lung
function
one
common
comorbid
found
diabet
patient
cazzola
et
al
strong
correl
sever
diabet
declin
fev
forc
vital
capac
fvc
kinney
et
al
particular
elderli
popul
caughey
et
al
like
result
reduct
activityrel
qualiti
life
cecer
et
al
mekov
et
al
consequ
reduc
fev
goe
far
beyond
effect
hyperglycaemia
lung
function
recent
demonstr
follow
studi
involv
nonsmok
zaigham
nilsson
wollmer
engstrom
report
low
fev
preced
significantli
predict
onset
diabet
heighten
notion
reduc
fev
could
pose
signific
risk
individu
develop
diabet
could
aris
mani
year
follow
initi
declin
lung
function
independ
smoke
histori
associ
diabet
declin
lung
function
link
multipl
level
name
system
inflamm
glucotox
insulin
resist
larg
bodi
evid
demonstr
system
inflamm
major
culprit
underli
impair
lung
function
diabet
akpinar
et
al
diabet
associ
persist
elev
inflammatori
mediat
crp
saltiel
olefski
turn
could
act
increas
vascular
permeabl
lung
sedgwick
menon
gern
buss
addit
induct
inflammatori
mediat
hyperglycaemia
insulin
resist
play
import
role
lung
patholog
one
hand
increas
blood
glucos
level
may
lead
rise
glucos
concentr
airway
secret
line
fluid
wood
brennan
philip
baker
shown
glucos
remain
undetect
level
normoglycaem
condit
high
mm
airway
secret
isol
condit
hyperglycaemia
indic
airway
glucos
threshold
may
exist
wood
et
al
moreov
increas
glucos
level
airway
secret
shown
contribut
impair
lung
function
mckeever
weston
hubbard
fogarti
hand
hyperglycaemia
may
also
result
format
glycosyl
endproduct
age
proinflammatori
natur
may
acceler
complic
lung
sparvero
et
al
insulin
resist
predomin
onset
diabet
result
chronic
elev
circul
basal
insulin
level
overcom
reduc
sensit
time
hypersecret
insulin
exhaust
pancreat
lead
declin
cell
mass
type
diabet
manifest
longer
abl
hypersecret
insulin
maintain
normal
concentr
glucos
blood
euglycemia
de
luca
olefski
henc
insulin
resist
import
featur
met
mark
prediabet
pulmonari
compart
insulin
exert
number
remodel
effect
airway
smooth
muscl
cell
stimul
prolifer
collagen
releas
well
contract
via
signal
contribut
airway
hyperrespons
singh
et
al
context
copd
declin
pulmonari
function
diseas
progress
increas
risk
alveolar
hypoxia
consequenti
hypoxemia
system
hypoxia
vogelmei
et
al
tissu
hypoxia
propos
respons
mani
maladapt
process
extrapulmonari
comorbid
character
copd
kent
mitchel
mcnichola
inde
chronic
hypoxia
produc
profound
chang
cellular
metabol
insulin
sensit
gileleshillel
kheirandishgoz
gozal
adipos
tissu
hypoxia
creat
state
insulin
resist
via
action
hypoxiainduc
factor
hif
basic
helixloophelix
transcript
factor
compos
subunit
wang
jiang
rue
semenza
normox
condit
subject
prolin
hydroxyl
lead
degrad
proteasom
hypoxia
inactiv
prolin
hydroxylas
lead
accumul
format
function
heterodimer
transcript
factor
kim
tchernyshyov
semenza
dang
hif
activ
hypoxia
decreas
phosphoryl
insulin
receptor
subsequ
blunt
downstream
signal
mediat
akt
result
reduc
glucos
transport
respons
insulin
stimul
regazzetti
et
al
liver
role
hypoxia
appear
complex
activ
hif
report
increas
hepat
insulin
sensit
via
induct
insulin
receptor
substrat
wei
et
al
despit
exacerb
hepat
lipid
accumul
attribut
induct
lipogen
gene
qu
et
al
taniguchi
et
al
skelet
muscl
exposur
hypoxia
tend
differenti
outcom
insulin
sensit
intermitt
hypoxia
demonstr
induc
insulin
resist
thoma
et
al
chronic
hypoxia
tend
increas
insulin
action
gamboa
garciacazarin
andrad
appar
differ
like
relat
sever
hypoxia
lecoultr
et
al
muscl
composit
gamboa
et
al
may
determin
adapt
outcom
skelet
muscl
note
augment
skelet
muscl
ampk
pathway
shown
counteract
detriment
effect
intermitt
hypoxia
wholebodi
glucos
toler
thoma
et
al
suggest
ampk
pathway
may
key
adapt
mechan
taken
togeth
find
offer
explan
least
part
posit
correl
observ
insulin
sensit
lung
function
forno
han
muzumdar
celedon
cvd
one
common
comorbid
chronic
inflammatori
diseas
regard
lead
caus
morbid
mortal
copd
patient
divo
et
al
schol
et
al
sin
anthonisen
soriano
agusti
coronari
arteri
diseas
hypertens
pulmonari
hypertens
heart
failur
probabl
frequent
occur
cardiovascular
disord
amongst
patient
copd
bhatt
dransfield
condit
sometim
overlap
presenc
one
condit
greatli
impact
qualityoflif
well
surviv
copd
patient
account
death
patient
mild
moder
copd
bhatt
dransfield
dalal
shah
lunacsek
hanania
de
lucasramo
et
al
although
differ
clinic
manifest
cvd
condit
relat
atherosclerosi
stiffen
vasculatur
due
build
plaqu
oxidis
ldl
deposit
plaqu
taken
macrophag
turn
lipidladen
foam
cell
result
stabil
collagenrich
fibrou
cap
larg
lipid
core
vessel
wall
dessi
et
al
mizuno
et
al
time
fibrou
cap
encapsul
enlarg
lipidrich
thrombogen
core
becom
vulner
ruptur
ruptur
atherosclerot
plaqu
lead
format
thrombu
associ
partial
complet
vessel
occlus
coronari
arteri
result
heart
attack
stroke
bhatt
dransfield
cigarett
smoke
exposur
import
risk
factor
atherosclerosi
initi
progress
due
oxid
stressinduc
proinflammatori
characterist
athyro
katsiki
et
al
chronic
low
grade
system
inflamm
present
copd
cvd
meanwhil
oxid
stress
major
contributor
copd
progress
also
shown
implic
cvd
zampetaki
dudek
mayr
inde
increas
system
inflamm
due
cigarett
smoke
demonstr
disrupt
stabil
vulner
plaqu
shift
vasculatur
toward
prothrombot
state
man
van
eeden
sin
mirrakhimov
mirrakhimov
importantli
cigarett
smoke
promot
system
inflamm
also
promot
dyslipidaemia
aforement
dyslipidaemia
inflamm
key
event
pathogenesi
atherosclerosi
dyslipidaemia
result
increas
avail
oxidis
ldl
develop
atherosclerot
plaqu
sustain
system
inflamm
pulmonari
impair
turn
system
inflamm
favour
exacerb
dyslipidaemia
form
yet
anoth
viscou
cycl
athyro
katsiki
et
al
dessi
et
al
make
matter
wors
hypoxia
may
aris
cigarett
smoke
declin
pulmonari
function
andor
vessel
occlus
due
atherosclerosi
shown
alter
pulmonari
blood
flow
result
right
ventricl
hypertrophi
left
ventricular
diastol
dysfunct
impact
cardiac
function
larsen
et
al
note
acut
exacerb
copd
due
secondari
infect
exposur
airborn
irrit
also
report
promot
myocardi
ischemia
mill
et
al
crosssect
longitudin
studi
demonstr
met
peopl
copd
worsen
respiratori
symptom
lung
function
due
amplifi
system
inflamm
cebron
lipovec
et
al
price
et
al
stanciu
et
al
amplifi
system
inflamm
feed
forward
exacerb
metabol
abnorm
dyslipidaemia
insulin
resist
saltiel
olefski
like
met
consequ
copd
base
follow
observ
met
life
style
dietari
relat
disord
experiment
evid
far
exist
support
dietari
andor
life
style
factor
directli
caus
copd
absenc
smoke
airborn
irrit
cigarett
smoke
import
modifi
risk
factor
met
smoke
cessat
shown
exert
benefici
effect
met
individu
compon
chen
et
al
heggen
svendsen
tonstad
ishizaka
et
al
next
part
review
focu
plausibl
pathogen
mechan
link
copd
met
multicentr
observ
studi
eclips
studi
investig
system
inflamm
distinct
phenotyp
amongst
clinic
stabl
copd
patient
faner
et
al
studi
found
copd
complex
heterogen
diseas
patient
copd
display
elev
marker
inflamm
fact
onethird
patient
manifest
evid
system
inflamm
follow
faner
et
al
major
patient
manifest
system
inflamm
system
elev
better
correl
cigarett
smoke
rather
copd
studi
also
identifi
distinct
pattern
system
inflamm
term
inflammom
consist
elev
white
blood
cell
count
plasma
crp
fibrinogen
may
use
good
biomark
mortal
exacerb
copd
agusti
et
al
importantli
patient
copd
studi
persist
system
inflamm
associ
much
wors
outcom
reflect
sixfold
increas
allcaus
mortal
year
follow
agusti
et
al
taken
togeth
find
eclips
studi
support
system
inflamm
import
driver
extrapulmonari
complic
sever
theori
propos
regard
underli
mechan
drive
system
inflamm
copd
predomin
theori
inflammatori
process
origin
airway
lung
parenchyma
spill
system
circul
bernardo
et
al
oh
sin
inde
sever
studi
report
associ
copd
lowgrad
system
inflamm
metaanalysi
studi
gan
man
senthilselvan
sin
found
patient
stabl
copd
increas
number
activ
leukocyt
increas
level
crp
cytokin
solubl
receptor
well
fibrinogen
intens
system
manifest
augment
exacerb
gan
et
al
wedzicha
et
al
spill
local
inflamm
circul
primari
attribut
increas
membran
permeabl
mention
previous
direct
damag
also
occur
pulmonari
compart
due
oxid
found
cigarett
smoke
excess
level
ro
reactiv
nitrogen
speci
rn
produc
result
pulmonari
system
inflamm
bernardo
et
al
cellular
inflamm
import
cue
manifest
system
inflamm
editori
henc
identifi
cellular
sourc
inflamm
may
key
arrest
system
patholog
import
cellular
sourc
inflammatori
mediat
copd
resid
recruit
macrophag
popul
copd
monocytemacrophag
lineag
heterogen
popul
cell
signific
phenotyp
plastic
acquir
function
phenotyp
depend
microenviron
vlaho
bozinovski
phenotyp
produc
proinflammatori
cytokin
eg
rn
ro
exhibit
strong
microbicid
tumoricid
activ
contrast
phenotyp
induc
express
antiinflammatori
cytokin
eg
molecul
eg
vegf
implic
tissu
repair
remodel
gordon
taylor
gener
glycolyt
metabol
support
polar
wherea
macrophag
predominantli
reli
mitochondri
oxid
phosphoryl
energi
metabol
reason
chang
metabol
propos
govern
phenotyp
immun
cell
control
transcript
posttranscript
event
central
activ
oneil
pearc
glanc
may
lead
us
think
cigarett
smoke
may
drive
system
inflamm
predominantli
influenc
glycolyt
metabol
immun
cell
resid
lung
particularli
alveolar
macrophag
howev
isol
smoker
exhibit
coordin
downregul
consider
number
gene
typic
polar
concomit
induct
panel
gene
typic
phenotyp
shaykhiev
et
al
suggest
cigarett
smoke
may
induc
reprogram
toward
line
experiment
evid
rodent
copd
model
found
increas
deposit
xie
lu
sun
intriguingli
recent
studi
also
observ
attenu
glycolyt
reserv
spare
respiratori
capac
smoker
lead
impair
glycolyt
respons
infect
gleeson
et
al
although
counter
intuit
find
entir
surpris
particularli
host
defenc
perspect
suppress
glycolyt
metabol
smoker
consist
epidemiolog
data
smoker
withwithout
copd
suscept
respiratori
tract
infect
nonsmok
murin
bilello
therefor
possibl
persist
lung
infect
might
develop
smoker
advanc
copd
due
deactiv
polar
program
turn
may
trigger
compensatori
inflammatori
respons
maladapt
natur
lead
excess
product
proinflammatori
mediat
chronic
inflamm
chronic
lowgrad
inflamm
hallmark
featur
obes
dyslipidaemia
insulin
resist
type
diabet
key
featur
met
fabbri
rabe
saltiel
olefski
past
decad
becom
increasingli
evid
system
inflamm
major
contributor
pathogenesi
met
lead
lifethreaten
diseas
cvd
cancer
hotamisligil
budavari
murray
spiegelman
pothiwala
jain
yaturu
roytblat
et
al
sartipi
loskutoff
serino
et
al
straczkowski
et
al
elev
level
crp
report
copd
patient
variou
degre
met
cazzola
et
al
kupe
et
al
stanciu
et
al
system
elev
uysal
wiesbrock
marino
hotamisligil
cai
et
al
shown
promot
insulin
resist
particularli
context
obes
chemotact
cytokin
respons
amplif
inflamm
via
recruit
activ
mononuclear
cell
similar
demonstr
directli
attenu
metabol
action
insulin
inhibit
receptor
signal
transduct
kobashi
et
al
moreov
chemotact
cytokin
respons
amplif
inflamm
via
recruit
activ
mononuclear
cell
could
also
result
worsen
insulin
resist
state
de
luca
olefski
releas
proinflammatori
cytokin
like
system
compart
mediat
distal
inflammatori
effect
includ
activ
hepat
gene
encod
acut
phase
reactant
includ
fibrinogen
crp
serum
amyloid
constitut
import
cue
onset
system
inflamm
gabay
kushner
crp
probabl
best
characteris
acut
phase
reactant
commonli
report
elev
condit
met
de
luca
olefski
crp
stimul
cytokin
releas
well
synthesi
cell
adhes
molecul
tissu
factor
monocyt
endotheli
cell
turn
could
activ
extrins
coagul
cascad
koh
meanwhil
laboratori
shown
serum
amyloid
highli
elev
aecopd
capabl
caus
skelet
muscl
atrophi
elicit
robust
proinflammatori
respons
driven
tolllik
receptor
may
explain
common
metabol
cvd
comorbid
two
diseas
contrari
improv
pulmonari
function
regular
physic
activ
balducci
et
al
recoveri
event
exacerb
perera
et
al
well
improv
bodi
mass
index
via
dietari
exercis
intervent
associ
reduct
system
inflamm
better
diseas
outcom
copd
met
patient
describ
elev
inflammatori
marker
crp
common
featur
copd
met
howev
marker
elev
greater
extent
obes
patient
rana
et
al
heighten
import
obes
process
inflamm
inde
abdomin
obes
shown
strongest
associ
lung
function
impair
leon
et
al
obes
regard
state
inflamm
character
lowgrad
chronic
inflamm
orchestr
metabol
tissuescel
respons
excess
nutrient
energi
gregor
hotamisligil
hotamisligil
adipos
tissu
respond
rapidli
dynam
nutrient
avail
particularli
condit
excess
adipos
tissu
expans
therebi
fulfil
major
role
wholebodi
energi
homeostasi
adipos
tissu
fat
depot
rather
endocrin
organ
activ
involv
wide
rang
metabol
process
includ
inflamm
insulin
sensit
lipid
metabol
blood
pressur
regul
kajimura
adipos
tissu
compris
adipocyt
macrophag
endotheli
cell
capabl
synthes
secret
protein
ie
adipokin
proinflammatori
cytokin
metabol
hormon
adiponectin
resistin
adipsin
leptin
growth
factor
vascular
endotheli
growth
factor
vegf
blood
pressur
regul
plasminogen
activ
compon
reninangiotensin
system
may
exert
local
system
effect
kajimura
adipos
tissu
expans
import
physiolog
process
respons
nutrit
surplu
allow
storag
excess
energi
fat
healthi
adipos
tissu
expans
highli
orchestr
process
effect
recruit
precursor
cell
adequ
angiogenesi
appropri
remodel
extracellular
matrix
howev
rapid
weight
gain
seen
obes
lead
patholog
adipos
tissu
expans
characteris
massiv
enlarg
hypertrophi
exist
adipocyt
sun
kusminski
scherer
rapid
rate
expans
often
outpac
rate
angiogenesi
result
poor
oxygen
local
hypoxia
within
deeper
part
tissu
halberg
et
al
kabon
et
al
adipos
tissu
hypoxia
form
cellular
stress
stimul
product
proinflammatori
mediat
macrophag
migrat
inhibitori
factor
vegf
tissu
inhibitor
leptin
monocyt
chemotact
protein
concomitantli
downregul
express
adiponectin
renown
antiinflammatori
adipokin
result
overal
shift
balanc
toward
inflamm
hosogai
et
al
lolmed
durand
de
saint
front
galitzki
lafontan
bouloumi
line
concept
acut
exacerb
copd
report
associ
increas
level
serum
leptin
increas
ratio
leptin
adiponectin
well
elev
classic
proinflammatori
marker
solubl
receptor
circul
krommida
et
al
yamauchi
et
al
contrari
increas
circulatori
level
adiponectin
detect
upon
resolut
exacerb
krommida
et
al
suggest
adipos
tissu
might
import
sourc
inflamm
copd
patient
weight
gain
issu
addit
promot
system
inflamm
adipocytereleas
cytokin
may
exert
neg
effect
metabol
exampl
may
increas
system
insulin
resist
promot
releas
fatti
acid
adipos
tissu
bloodstream
act
tissu
muscl
liver
gregor
hotamisligil
hotamisligil
shargil
spiegelman
also
potent
stimulu
product
releas
adipocyt
bruun
pedersen
kristensen
richelsen
turn
promot
releas
fatti
acid
adipos
tissu
lipolysi
greenberg
et
al
furthermor
also
demonstr
promot
synthesi
leptin
adipos
tissu
zumbach
et
al
leptin
strong
immunoregulatori
activ
upregul
express
proinflammatori
cytokin
loffreda
et
al
note
increas
circulatori
leptin
level
correl
impair
lung
function
sin
man
previou
experiment
clinic
research
indic
involv
leptin
bodi
weight
homeostasi
leptin
hormon
produc
adipos
tissu
respons
regul
energi
balanc
feedback
mechan
involv
hypothalamu
normal
leptin
feedback
mechan
disturb
sever
factor
rodent
administr
endotoxin
proinflammatori
cytokin
like
result
dosedepend
upregul
leptin
mrna
adipos
tissu
elev
circul
leptin
concentr
grunfeld
et
al
sarraf
et
al
stabl
patient
emphysema
leptin
found
posit
associ
solubl
tnf
schol
et
al
henc
disturb
leptin
feedback
mechan
might
offer
explan
least
part
augment
leptin
level
particularli
episod
exacerb
system
inflammatori
respons
may
pronounc
stabl
patient
saetta
et
al
contrast
leptin
adiponectin
probabl
adipocytederiv
factor
demonstr
antiinflammatori
properti
adiponectin
reduc
product
activ
inhibit
product
induc
product
antiinflammatori
cytokin
epitheli
cell
monocytesmacrophag
takeda
nakanishi
tachibana
kumanogoh
wolf
wolf
rumpold
enrich
tilg
human
anim
model
adiponectin
promot
wholebodi
insulin
sensit
glucos
homeostasi
kadowaki
et
al
angiogen
effect
adiponectin
also
help
improv
vascular
adipos
tissu
expans
prevent
onset
inflamm
due
local
hypoxia
kim
et
al
grow
bodi
evid
demonstr
adiponectin
may
also
act
endotheli
cell
maintain
vascular
homoeostasi
offer
protect
vascular
dysfunct
commonli
associ
copd
met
kim
et
al
inde
adiponectin
invers
associ
smoke
diabet
incid
may
also
probabl
mediat
associ
current
smoke
met
hilaw
et
al
interest
sever
anim
studi
detect
express
leptin
receptor
lung
tissu
chelikani
glimm
kennelli
henson
et
al
hoggard
et
al
human
differ
leptin
receptor
isoform
found
express
airway
smooth
muscl
cell
nair
et
al
epitheli
cell
submucosa
lung
bruno
et
al
although
function
signific
receptor
present
unknown
exist
leptin
receptor
indic
lung
may
also
target
organ
leptin
signal
malli
papaioann
gourgouliani
daniil
support
leptin
receptor
adiponectin
found
express
lung
miller
cho
pham
ramsdel
broid
importantli
leptin
express
increas
bronchial
mucosa
copd
patient
function
leptin
signal
pathway
demonstr
exist
lung
epitheli
cell
vernooy
et
al
moreov
experiment
evid
indic
adiponectin
may
attenu
airway
inflamm
airway
hyperrespons
mice
follow
allergen
exposur
shore
terri
flynt
xu
hug
find
suggest
exist
crosstalk
adipos
tissu
lung
may
serv
mechanist
link
inflammatori
basi
copd
met
addit
local
adipos
tissu
hypoxia
system
hypoxia
result
reduc
pulmonari
function
also
believ
import
cue
proinflammatori
cytokin
express
bernardo
et
al
howev
present
unclear
whether
system
hypoxia
exert
addit
multipl
effect
adipos
tissu
patient
copd
concurr
obes
tkacova
perhap
experiment
evid
deriv
sleep
apnoea
may
shed
light
upon
wellestablish
intermitt
system
hypoxia
result
sleep
apnoea
associ
system
inflamm
da
rosa
et
al
gileleshillel
et
al
perrini
et
al
importantli
intermitt
system
hypoxia
may
profoundli
impact
metabol
homeostasi
chronic
intermitt
hypoxia
promot
dysregul
lipid
li
et
al
cholesterol
biosynthesi
impair
insulin
sensit
murphi
et
al
well
disrupt
normal
diurnal
rhythm
lead
hyperglycaemia
rais
suscept
pancreat
hypoxiainduc
death
yoko
et
al
also
evid
suggest
adipos
tissu
becom
inflam
respons
intermitt
hypoxia
turn
drive
onset
insulin
resist
murphi
et
al
find
suggest
adipos
tissu
dysfunct
import
mechan
diseas
develop
studi
warrant
analys
adipos
tissu
inflamm
stabl
copd
acut
exacerb
oxid
stress
imbal
oxid
antioxid
level
favour
prooxid
environ
cell
tissu
srinivasan
et
al
copd
patient
oxid
stress
may
aris
inhal
oxid
cigarett
smoke
airborn
irrit
result
host
inflammatori
respons
activ
leukocyt
releas
ro
bernardo
et
al
uncontrol
oxid
caus
direct
damag
lung
oxid
cellular
compon
molecul
lead
activ
signal
pathway
mediat
result
product
proinflammatori
mediat
aforement
favour
develop
system
inflamm
cyphert
et
al
man
et
al
oh
sin
oxid
stress
also
appar
met
unlik
copd
oxid
stress
context
mainli
aris
activ
specif
biochem
pathway
eg
oxid
metabol
mitochondria
increas
cellular
product
result
inflamm
exhaust
cellular
antioxid
mechan
well
lipid
peroxid
typic
seen
obes
furukawa
et
al
due
proinflammatori
natur
presenc
oxid
stress
suggest
probabl
link
increas
cardiovascular
comorbid
risk
copd
met
hutcheson
rocic
one
hand
prolong
increas
oxid
stress
due
cigarett
smoke
shown
promot
develop
diabet
via
upsurg
insulin
resist
hand
oxid
stress
met
may
caus
impair
pulmonari
function
activ
inflamm
cyphert
et
al
kim
et
al
kobashi
et
al
mina
et
al
close
interrelationship
copd
met
discuss
far
may
favour
cigarett
smoke
link
diseas
inde
oxid
properti
cigarett
smoke
crucial
initi
copd
vogelmei
et
al
time
cigarett
smoke
also
independ
modifi
risk
factor
met
willi
bodenmann
ghali
fari
cornuz
howev
cigarett
smoke
current
recogn
link
copd
met
cazzola
et
al
indic
work
need
area
regular
physic
activ
offer
mani
health
benefit
reduc
risk
variou
comorbid
dietz
dougla
brownson
howev
copd
patient
report
reduc
physic
activ
hamper
presenc
concurr
met
clini
et
al
well
recognis
loss
fatfre
mass
contribut
muscl
weak
reduc
exercis
capac
condit
known
muscl
wast
patient
moder
sever
copd
passey
et
al
obes
patient
copd
increas
contractil
muscl
effort
requir
sustain
ventil
exercis
overcom
seriou
mechan
constraint
airflow
obstruct
result
patient
present
sever
incapacit
dyspnoea
exercis
compar
nonobes
patient
copd
monteiro
et
al
therefor
copd
may
increas
propens
weight
gain
obes
limit
physic
activ
thu
predispos
patient
develop
met
return
met
place
constraint
physic
activ
turn
would
contribut
declin
pulmonari
function
promot
progress
copd
sever
hartman
et
al
contrari
regular
physic
activ
well
document
counteract
system
inflamm
pulmonari
dysfunct
muscl
wast
passey
et
al
increas
level
physic
activ
associ
reduc
level
crp
neg
prognost
factor
develop
cardiovascular
comorbid
copd
patient
abramson
vaccarino
ford
furthermor
patient
met
modest
exercis
reduc
peripher
marker
inflamm
name
troseid
et
al
importantli
exercis
train
proven
benefici
copd
patient
term
pulmonari
function
qualiti
life
owe
least
part
improv
peripher
muscl
function
passey
et
al
perspect
glucos
homeostasi
muscl
major
organ
glucos
util
energi
expenditur
increas
exercis
capac
due
improv
muscl
function
restor
glucos
metabol
via
mean
insulindepend
independ
mechan
holloszi
regular
physic
activ
demonstr
exert
protect
effect
oxid
stress
via
induct
antioxid
pathway
de
sousa
et
al
combin
proper
dietari
regim
exercis
train
also
effect
combat
obes
achiev
better
weightcontrol
well
restor
endotheli
function
greatli
reduc
individu
risk
cardiovascular
comorbid
johansson
neoviu
hemmingsson
moienafshari
et
al
meanwhil
better
weightcontrol
also
confer
better
qualiti
life
copd
patient
taken
togeth
experiment
epidemiolog
evid
demonstr
impair
physic
activ
key
factor
pathogenesi
met
copd
patient
inhal
oral
glucocorticoid
use
frequent
inadequ
treat
patient
copd
multicentr
studi
involv
mild
copd
patient
euroscop
pauwel
et
al
demonstr
inhal
glucocorticoid
offer
longterm
benefit
lung
function
declin
three
year
follow
despit
small
shortterm
benefit
moderatesever
copd
cohort
isold
studi
burg
et
al
report
glucocorticoid
affect
rate
fev
declin
associ
fewer
exacerb
slower
declin
health
statu
contrari
torch
studi
calverley
et
al
conduct
patient
moderatesever
copd
patient
found
glucocorticoid
therapi
associ
slower
declin
fev
howev
benefit
translat
better
surviv
rate
patient
receiv
glucocorticoid
medic
contain
fluticason
greater
risk
pneumonia
overal
shortterm
improv
lung
function
may
help
shorten
hospit
stay
may
provid
support
use
glucocorticoid
therapi
patient
experienc
aecopd
howev
excess
use
glucocorticoid
profound
effect
paramet
metabol
syndrom
di
dalmazi
pagotto
pasquali
vicennati
firstli
glucocorticoid
impair
pancreat
function
disrupt
uptak
metabol
glucos
van
raalt
ouwen
diamant
secondli
glucocorticoid
shown
exert
antiinsulin
action
liver
skelet
muscl
adipos
tissu
mazziotti
gazzaruso
giustina
key
organ
maintain
metabol
homeostasi
disrupt
insulin
action
organ
profound
metabol
consequ
particularli
postprandi
state
insulin
promot
uptak
storag
glucos
glycogen
muscl
triglycerid
adipos
tissu
lipolysi
concomitantli
repress
via
inhibit
fatti
acid
releas
enzym
importantli
insulin
also
supress
hepat
gluconeogenesi
glycogenolysi
aid
glycaem
control
fed
state
petersen
vatner
shulman
failur
render
develop
insulin
resist
antiinsulin
action
glucocorticoid
one
hand
dampen
activ
key
signal
molecul
upon
insulin
receptor
activ
name
insulin
receptor
pathway
result
impair
transloc
glucos
transport
cell
surfac
decreas
glucos
uptak
tissu
mazziotti
et
al
petersen
et
al
hand
glucocorticoid
stimul
activ
ratelimit
enzym
involv
gluconeogenesi
phosphoenolpyruv
carboxykinas
pepck
cassuto
et
al
thirdli
glucocorticoid
oppos
suppress
effect
insulin
stimul
lipolysi
adipos
tissu
caus
elev
free
fatti
acid
contribut
impair
glucos
uptak
peripher
tissu
contribut
hyperglycaemia
mazziotti
et
al
lipolyt
effect
glucocorticoid
also
promot
abnorm
distribut
bodi
fat
toward
viscer
depot
mazziotti
et
al
creat
centralabdominalobes
centralobes
preval
manifest
met
reflect
dysfunct
adipos
tissu
favour
develop
insulin
resist
despr
lemieux
strikingli
cigarett
smoke
link
preferenti
deposit
viscer
fat
smoker
often
abdomin
adipos
mass
nonsmok
even
adjust
total
adipos
barrettconnor
khaw
shimokata
muller
andr
final
glucocorticoid
may
interfer
express
activ
profil
adipos
tissuederiv
cytokin
ie
adipokin
adiponectin
leptin
turn
may
impair
insulin
sensit
bianco
et
al
mazziotti
et
al
takeda
et
al
addit
exogen
administr
endogen
biosynthesi
degrad
steroid
hormon
also
appear
play
role
develop
met
tobacco
contain
dehydrogenas
type
inhibitor
glycyrrhiz
acid
inhibit
convers
cortisol
inact
cortison
gilbert
lim
lead
prolong
bioavail
extend
activ
moreov
persist
hypoxia
may
increas
catecholamin
output
kanstrup
et
al
lead
develop
hyperglycaemia
via
inhibit
action
insulin
barth
et
al
regardless
sourc
hypercortisol
result
either
exogen
endogen
origin
caus
proxim
muscl
weak
mazziotti
et
al
may
pose
addit
constraint
individu
daili
activ
level
increas
propens
complic
whole
evid
suggest
abnorm
steroid
hormon
metabol
action
like
miss
link
connect
copd
met
hyperglycaemia
condit
character
elev
blood
glucos
concentr
diagnost
featur
type
diabet
first
evid
suggest
concept
alter
pulmonari
function
may
preced
onset
met
come
prospect
studi
lung
function
diabet
adult
yeh
et
al
follow
use
mous
model
proinflammatori
cytokin
specif
overexpress
lung
takenaka
et
al
takenaka
et
al
observ
sever
emphysemat
chang
pulmonari
hypertens
pulmonari
dysfunct
mice
featur
seen
human
copd
importantli
mice
went
develop
glucos
intoler
later
life
provid
compel
evid
support
direct
causal
relationship
pulmonari
inflamm
metabol
disturb
essenti
aforedescrib
mechan
directli
caus
contribut
manifest
hyperglycaemia
proinflammatori
cytokin
leptin
oxid
stress
use
steroid
medic
endogen
hormon
imbal
disrupt
glucos
homeostasi
interf
insulin
action
mirrakhimov
fact
hyperglycemia
major
side
effect
glucocorticoid
medic
use
aecopd
baker
et
al
diminish
physic
activ
aris
condit
may
offer
anoth
plausibl
mechan
continu
hyperglycaemia
regular
physic
activ
less
sedentari
time
associ
reduc
risk
comorbid
park
larson
hyperglycaemia
golden
hallmark
onset
diabet
moreov
persist
hyperglycaemia
give
rise
seriou
complic
cvd
neuropathi
nephropathi
result
mortal
impact
end
develop
hyperglycaemia
may
turn
potenti
pathogenesi
clinic
cours
copd
experiment
evid
human
demonstr
hyperglycaemia
stimul
proinflammatori
cytokin
includ
circul
esposito
et
al
separ
studi
increas
level
crp
detect
individu
impair
fast
glucos
level
andreozzi
et
al
choi
et
al
suggest
system
inflamm
hyperglycaemia
line
diabet
patient
aecopd
report
frequent
display
hyperglycaemia
studi
case
hospit
stay
also
associ
extend
length
hospit
mortal
compar
nondiabet
patient
baker
et
al
parappil
et
al
moreov
blood
glucos
level
mm
found
significantli
correl
advers
aecopd
outcom
chakrabarti
angu
agarw
lane
calverley
moreov
relationship
mark
increas
risk
death
andor
long
inpati
stay
everi
increment
blood
glucos
baker
et
al
retrospect
studi
administr
claim
data
australian
govern
depart
veteran
affair
also
reveal
copd
patient
diabet
significantli
increas
risk
diabetesrel
hospit
upon
highdos
corticosteroid
therapi
caughey
preiss
vitri
gilbert
roughead
addit
system
inflamm
vivo
studi
demonstr
chronic
hyperglycaemia
trigger
endotheli
dysfunct
blood
vessel
diabet
patient
via
excess
gener
ro
ceriello
nevertheless
signific
consequ
hyperglycaemia
still
lie
impact
pulmonari
function
increas
level
ro
induc
hyperglycaemia
lead
activ
cellular
stress
pathway
mediat
mapk
impair
pulmonari
function
tiengo
fadini
avogaro
isol
human
bronchi
high
glucos
concentr
lead
enhanc
respons
airway
smooth
muscl
cell
contractil
agent
via
specif
cellular
pathway
mediat
rhokinas
cazzola
et
al
enhanc
airway
hyperrrespons
major
risk
factor
acceler
declin
pulmonari
function
seen
copd
patient
furthermor
hyperglycaemia
may
also
increas
risk
pulmonari
infect
render
appear
glucos
airway
secret
make
respiratori
tract
vulner
infecti
exacerb
cazzola
et
al
mckeever
et
al
final
hyperglycaemia
may
also
target
diaphragm
major
respiratori
muscl
oxid
stress
inflamm
inflict
hyperglycaemia
result
sarcomer
injuri
via
activ
proteolyt
machineri
lead
contractil
protein
wast
consequ
loss
forc
gener
capac
diaphragm
fiber
patient
copd
ottenheijm
heunk
dekhuijzen
find
strengthen
strike
observ
pulmonari
function
impair
promin
patient
poorli
control
blood
glucos
level
independ
obes
age
rogliani
calzetta
segreti
barril
cazzola
hypogonad
condit
androgen
defici
combin
otherwis
unexplain
fatigu
diminish
energi
diminish
sens
vital
diminish
sens
wellb
commonli
experienc
patient
copd
laghi
et
al
hypogonad
aris
declin
serum
testosteron
frequent
associ
age
chronic
ill
rhoden
morgental
preval
hypogonad
copd
patient
rang
associ
sever
system
manifest
includ
osteoporosi
depress
muscl
weak
balasubramanian
na
addit
age
potenti
caus
hypogonad
copd
includ
system
hypoxia
hypercapnia
glucocorticoid
therapi
balasubramanian
na
system
inflamm
underli
driver
agusti
barn
celli
indic
copd
condit
might
give
rise
hypogonad
howev
lack
correl
report
testosteron
level
sever
airway
obstruct
suggest
hypogonad
may
directli
contribut
respiratori
symptom
van
vliet
et
al
age
muscl
weak
system
hypoxia
glucocorticoid
use
system
inflamm
pathogen
cue
met
possibl
met
might
serv
connect
piec
puzzl
longitudin
studi
involv
male
patient
variou
stage
diseas
without
addit
intervent
three
year
found
low
testosteron
level
strongli
correl
higher
bmi
spearman
r
meanwhil
correl
found
testosteron
level
fev
separ
studi
involv
middleag
men
stabl
copd
greater
bmi
also
observ
patient
hypogonad
compar
without
laghi
et
al
moreov
report
hypogonad
close
link
met
hypogonad
individu
risk
diabet
due
unfavour
chang
bodi
composit
promot
accumul
bodi
fat
decreas
muscl
mass
concomit
decreas
insulin
sensit
muscl
strength
oxygen
consumpt
capac
bojesen
host
gravholt
meanwhil
met
also
shown
promot
develop
hypogonad
gautier
et
al
reason
hypogonad
propos
fundament
compon
met
inde
testosteron
therapi
shown
great
potenti
slow
halt
progress
metabol
syndrom
overt
complic
fullblown
diabet
cardiovascular
diseas
via
benefici
effect
insulin
regul
lipid
profil
blood
pressur
makhsida
shah
yan
fisch
shabsigh
evid
suggest
level
testosteron
may
play
pivot
role
develop
met
particularli
age
patient
copd
contrari
femal
sexhormon
also
appear
impact
lung
physiolog
chronic
exposur
mice
cigarett
smoke
report
induc
emphysematouslik
chang
alveolar
structur
rapidli
femal
male
carey
et
al
partli
explain
observ
estradiol
may
upregul
cytochrom
enzym
turn
make
femal
lung
suscept
oxid
damag
respons
cigarett
smoke
van
winkl
gunderson
shimizu
baker
brown
sever
key
piec
evid
recent
suggest
coexist
met
worsen
progress
prognosi
copd
first
neg
impact
diabet
copd
clearli
demonstr
eclips
studi
larg
multicentr
investig
sought
defin
distinct
phenotyp
identifi
biomark
predict
progress
copd
cohort
consist
clinic
stabl
copd
subject
well
smoker
nonsmok
normal
lung
function
studi
identifi
diabet
increas
odd
mortal
coexist
copd
faner
et
al
moreov
diabet
also
found
associ
greater
dyspnoea
score
reduc
walk
distanc
indic
pulmonari
function
declin
note
pulmonari
function
declin
evidenc
reduc
fev
also
relat
increas
requir
inhal
glucocorticoid
control
diseas
cecer
et
al
turn
favour
continu
met
moreov
pulmonari
hypertens
found
sever
patient
concurr
copd
diabet
makarevich
et
al
coexist
met
particularli
hyperglycaemia
typic
seen
poorli
control
diabet
greatli
increas
length
hospit
risk
mortal
patient
aecopd
baker
et
al
parappil
et
al
associ
exacerb
advanc
age
stojkovikj
et
al
vogelmei
et
al
importantli
increas
preval
met
amongst
younger
popul
zimmet
alberti
despit
less
sever
copd
younger
patient
met
higher
circul
level
leptin
lower
fig
summari
therapeut
strategi
may
benefit
met
copd
outcom
system
inflamm
hypoxemia
physic
inact
result
cigarett
smoke
may
profound
impact
metabol
homeostasi
cellular
level
event
promot
impair
mitochondri
function
biogenesi
lead
excess
product
ro
deplet
cellular
antioxid
defenc
give
rise
oxid
stress
oxid
stress
inhibit
major
metabol
pathway
glucos
metabol
insulin
ii
activ
cellular
proinflammatori
pathway
mediat
iii
damag
cell
oxid
modif
protein
dna
lipid
iv
activ
adapt
pathway
gener
catabol
natur
inflamm
gener
cytokin
exacerb
system
inflamm
caus
amplif
diseas
coexist
obes
may
enforc
onset
metabol
derang
may
acceler
system
manifest
copd
relat
comorbid
henc
number
strategi
develop
target
variou
contributori
aspect
copd
met
far
experiment
clinic
evid
support
revers
metabol
derang
viabl
therapeut
strategi
treat
copd
comorbid
may
benefit
outcom
copd
level
adiponectin
increas
insulin
resist
reflect
homeostat
model
assess
homa
index
compar
patient
without
met
mina
et
al
convers
literatur
also
indic
copd
may
import
risk
factor
onset
continu
met
breyer
et
al
cebron
lipovec
et
al
taken
togeth
met
repres
import
mechan
neg
outcom
seen
copd
patient
reason
patient
concurr
exist
condit
treat
highrisk
place
close
monitor
cigarett
smoke
recogn
modifi
risk
factor
met
harri
zopey
friedman
copd
vogelmei
et
al
earli
smoke
cessat
theori
address
much
patholog
aris
diseas
inde
smoke
cessat
regard
firstlin
treatment
avoid
reduc
progress
copd
vogelmei
et
al
smoke
cessat
effect
lower
risk
cardiovascular
comorbid
lung
cancer
fig
benefit
cvd
almost
immedi
within
hour
smoke
cessat
signific
improv
blood
pressur
heart
rate
within
one
year
abstin
risk
cardiovascular
event
myocardi
infarct
stroke
reduc
half
compar
continu
smoke
year
postsmok
risk
stroke
coronari
heart
diseas
normal
never
smoker
wu
sin
howev
full
benefit
tobacco
treatment
may
realiz
mani
year
abstin
exampl
benefit
smoke
cessat
risk
lung
cancer
might
evidenc
year
abstin
anthonisen
et
al
probabl
partli
explain
presenc
ongo
airway
inflamm
exsmok
godtfredsen
et
al
inde
controversi
exist
whether
patholog
airway
inflamm
may
benefit
smoke
cessat
due
oppos
find
literatur
gambl
et
al
turato
et
al
willems
et
al
like
influenc
smoke
histori
cessat
complianc
ethnic
underli
factor
genet
suscept
yang
holloway
fong
nonetheless
smoke
cessat
copd
patient
gener
associ
slower
rate
pulmonari
function
declin
lung
inflamm
oxid
stress
anthonisen
et
al
athyro
katsiki
et
al
godtfredsen
et
al
turn
lead
improv
surviv
rate
compar
continu
smoker
godtfredsen
et
al
metabol
front
smoke
cessat
known
benefici
effect
insulin
sensit
howev
often
accompani
paradox
bodi
weight
gain
could
render
subsequ
reemerg
insulin
resist
harri
et
al
due
profound
effect
nicotin
exposur
metabol
nicotin
stimul
activ
lipoprotein
lipas
break
triglycerid
form
free
fatti
acid
time
nicotin
promot
energi
expenditur
product
leptin
adipos
tissu
stimul
releas
catecholamin
liu
mizuta
matsukura
nicotin
also
activ
nicotin
acetylcholin
receptor
hypothalamu
lead
activ
proopiomelanocortin
pomc
neuron
pomc
neuron
subsequ
activ
melanocortin
receptor
lead
suppress
appetit
mineur
et
al
appetit
suppress
effect
nicotin
reinforc
high
level
leptin
circul
wynn
stanley
mcgowan
bloom
weight
loss
gener
associ
improv
metabol
paramet
insulin
sensit
gregor
hotamisligil
monteiro
et
al
sun
et
al
howev
weight
loss
mediat
nicotin
attribut
loss
skelet
muscl
mass
passey
et
al
redistribut
fat
mass
favour
viscer
accumul
audrainmcgovern
benowitz
result
metabol
disturb
smoke
cessat
withdraw
nicotin
decreas
metabol
expenditur
restor
appetit
lead
posit
energi
balanc
increas
propens
postcess
weight
gain
harri
et
al
although
undesir
postcess
weight
gain
manag
dietari
exercis
intervent
emphas
calor
control
energi
expenditur
johansson
et
al
maatman
et
al
despit
impact
metabol
must
point
postcess
weight
gain
still
far
less
harm
smoke
benefit
associ
individu
health
social
economi
quit
clearli
outweigh
counterpart
us
depart
health
human
servic
inflammatori
natur
met
copd
attract
much
interest
cytokineneutralis
therapi
possibl
treatment
diseas
genet
obes
rat
neutral
restor
insulinstimul
glucos
uptak
hotamisligil
et
al
insulin
sensit
peripher
tissu
hotamisligil
et
al
tnf
neutral
human
associ
reduc
system
inflamm
howev
efficaci
insulin
sensit
appear
inconclus
studi
report
improv
kiortsi
mavridi
vasako
nika
droso
oguz
oguz
uzunlulu
stagaki
et
al
stavropouloskalinogl
et
al
tam
tomlinson
chu
li
li
other
show
littl
effect
ferrazamaro
et
al
rosenving
kroghmadsen
baslund
pedersen
seriolo
ferron
cutolo
reason
behind
discrep
fullyunderstood
howev
like
influenc
degre
sever
insulin
resist
onset
therapi
well
coexist
underli
condit
obes
wascher
et
al
copd
context
neutral
therapi
infliximab
fail
improv
diseas
outcom
patient
includ
symptom
score
pulmonari
function
exercis
capac
dyspnoea
score
health
statu
rate
acut
exacerb
rennard
et
al
despit
mark
efficaci
demonstr
experiment
cigarett
smoke
model
churg
et
al
moreov
neutral
therapi
shown
ineffect
reduc
local
system
inflamm
copd
patient
loza
watt
baribaud
barnathan
rennard
lack
overal
clinic
benefit
lung
patholog
rennard
et
al
lack
clinic
efficaci
one
hand
may
relat
time
therapeut
intervent
relat
diseas
sever
passey
et
al
meanwhil
appear
marker
cigarett
smoke
rather
copd
faner
et
al
suggest
may
suitabl
target
treat
copd
noteworthi
chronic
neutral
also
associ
increas
risk
pneumonia
lung
malign
copd
patient
durham
caramori
chung
adcock
current
use
treatment
met
copd
neutralis
therapi
shown
promis
treatment
cancer
cachexia
bayliss
et
al
bayliss
smith
schuster
dragnev
riga
report
use
humanis
monoclon
antibodi
high
affin
bind
clinic
trial
focus
nonsmal
cell
lung
cancer
antibodi
therapi
well
toler
amelior
key
patholog
aris
diseas
anaemia
cachexia
contribut
better
surviv
rate
meanwhil
receptor
antibodi
tocilizumab
shown
benefici
cachexia
cancer
patient
ando
et
al
given
demonstr
bona
fide
biomark
copd
aecopd
neutralis
cytokin
benefit
copd
met
fig
likewis
neutralis
antibodi
also
develop
test
clinic
trial
hong
et
al
demonstr
antibodi
therapi
effect
reduc
marker
system
inflamm
doselimit
toxic
experienc
amongst
test
subject
importantli
cancer
patient
receiv
therapi
gradual
increas
lean
bodi
mass
concomit
reduct
fat
mass
assess
dual
energi
xray
absorptiometri
dexa
scan
patient
also
experienc
improv
overal
energi
level
gener
qualiti
life
score
indic
therapi
may
benefit
muscl
mass
function
muscl
mass
function
critic
import
maintain
metabol
homeostasi
pulmonari
physiolog
find
strengthen
rational
use
neutralis
therapi
patient
met
copd
support
neutralis
therapi
shown
effect
attenu
inflamm
result
virusinduc
exacerb
cigarett
smokeexpos
mice
botelho
et
al
metformin
recommend
firstlin
treatment
type
diabet
patient
american
diabet
associ
sonn
hemmingsen
metformin
antihyperglycaem
agent
improv
glucos
toler
patient
type
diabet
lower
basal
postprandi
plasma
glucos
level
belong
biguanid
class
pharmacolog
mechan
action
includ
suppress
hepat
glucos
product
reduct
intestin
absorpt
glucos
improv
insulin
sensit
increas
peripher
glucos
uptak
util
viollet
et
al
addit
use
drug
also
found
reduc
risk
cardiovascular
event
mortal
holman
paul
bethel
matthew
neil
despit
occurr
lactic
acidosi
rare
case
frid
et
al
given
pulmonari
function
declin
copd
may
promot
poor
oxygen
metabol
tissu
favour
product
lactic
acid
anaerob
metabol
glucos
hitch
archer
srivastava
baker
rais
safeti
concern
use
metformin
copd
british
nation
formulari
us
feder
drug
administr
advis
metformin
withheld
promptli
presenc
condit
associ
hypoxemia
light
recent
studi
conduct
hitch
et
al
hitch
et
al
investig
safeti
metformin
copd
retrospect
cohort
patient
studi
found
metformin
therapi
among
patient
copd
high
risk
lactat
accumul
associ
minor
elev
lactat
concentr
doubt
clinic
signific
suggest
safeti
metformin
use
copd
addit
proinflamm
hyperglycaemia
also
mediat
increas
glucos
airway
surfac
liquid
make
respiratori
tract
copd
patient
vulner
infecti
exacerb
cazzola
et
al
mckeever
et
al
metformin
treatment
shown
direct
effect
glucos
flux
across
airway
epithelium
limit
hyperglycaemiainduc
bacteri
growth
respons
respiratori
infect
garnett
et
al
retrospect
investig
involv
patient
concurr
copd
met
treatment
hypoglycaem
agent
independ
associ
improv
fvc
kim
et
al
moreov
prospect
observ
studi
metformin
administr
improv
dyspnoea
respiratori
muscl
strength
copd
patient
diabet
sexton
metcalf
kolb
metformin
also
found
possess
import
antiinflammatori
antioxid
properti
may
account
efficaci
observ
cellular
level
metformin
shown
directli
inhibit
mediat
signal
product
via
activ
ampk
huang
et
al
type
diabet
subject
metformin
administr
reduc
appear
urinari
biomark
oxid
stress
formoso
et
al
metformin
might
therefor
addit
benefit
prevent
treatment
respiratori
disord
fig
given
observ
newli
diagnos
diabet
patient
characteris
diminish
endogen
insulin
product
frequent
impair
pulmonari
function
tiengo
et
al
insulin
therapi
demonstr
improv
alveolarcapillari
membran
ga
conduct
guazzi
oreglia
guazzi
possibl
insulin
administr
treatment
respiratori
disord
explor
disappointingli
inhal
human
insulin
associ
respiratori
symptom
includ
cough
mild
dyspnoea
along
reduct
fev
diffus
capac
lung
carbon
monoxid
surrog
marker
alveolarcapillari
membran
function
ceglia
lau
pitta
mode
insulin
deliveri
also
present
number
undesir
effect
includ
difficulti
dosag
control
tendenc
hypoglycaemia
could
fatal
henc
research
need
determin
safeti
benefit
inhal
insulin
therapi
diabet
patient
copd
sinc
abnorm
inflammatori
respons
cigarett
smoke
may
aris
reprogram
toward
polar
phenotyp
polar
close
depend
state
cellular
metabol
metabol
reprogram
macrophag
immun
cell
may
plausibl
therapeut
strategi
disconnect
copd
met
comorbid
note
modul
glycolysi
tan
et
al
mitochondri
oxid
phosphoryl
vat
et
al
via
genet
manipul
demonstr
suffici
produc
phenotyp
switch
macrophag
addit
convent
genet
pharmacolog
approach
recent
studi
saborano
et
al
saborano
et
al
demonstr
metabol
reprogram
macrophag
achiev
nanoparticl
specif
diamet
howev
benefit
manipul
system
inflamm
copd
comorbid
remain
determin
oxid
stress
attribut
imbal
oxid
antioxid
restor
balanc
offer
hope
prevent
treat
multipl
diseas
reason
therapeut
approach
aim
replenish
deplet
nonenzymat
defenc
dietari
pharmacolog
mean
increas
endogen
antioxid
enzym
activ
via
enzym
modulatorsmimet
bernardo
et
al
given
renown
radic
scaveng
properti
vitamin
vitamin
extens
studi
howev
disappoint
result
obtain
vitamin
supplement
alik
dietari
antioxid
demonstr
littletono
effect
metabol
paramet
includ
bodi
weight
glycaemia
plasma
lipid
profil
patient
met
avignon
hokayem
bisbal
lambert
man
et
al
vitamin
supplement
also
appear
insuffici
benefit
cardiovascular
complic
associ
met
debreceni
debreceni
likewis
administr
vitamin
dietari
antioxid
also
shown
minim
improv
either
copd
comorbid
rahman
macne
contrast
vitamin
flavonoid
polyphenol
supplement
shown
efficaci
counteract
metabol
abnorm
well
cardiovascular
dysfunct
human
anim
met
resveratrol
naturallyoccur
polyphenol
found
red
wine
grape
skinse
administr
resveratrol
deriv
mice
normalis
left
ventricular
hypertrophi
interstiti
fibrosi
diastol
dysfunct
induc
diet
high
fat
sugar
benefici
effect
associ
decreas
oxidantmedi
protein
modif
hyperinsulinemia
concomit
increas
plasma
adiponectin
indic
improv
insulin
sensit
qin
et
al
similarli
resveratrol
supplement
lower
adipos
serum
cholesterol
creactiv
protein
level
along
improv
glucos
toler
endotheli
function
swine
model
met
myocardi
ischemia
robich
et
al
moreov
eight
week
administr
resveratrol
highfructos
fed
rat
result
remark
improv
glucos
toler
plasma
insulin
lipid
level
well
enhanc
hepat
catalas
superoxid
dismutas
sod
enzym
activ
reflect
attenu
oxid
stress
anim
bagul
et
al
importantli
attenu
oxid
stress
found
resveratroltr
group
metformintr
group
bagul
et
al
suggest
differ
mode
action
despit
agent
appear
activ
ampk
human
moder
redwin
consumpt
suggest
protect
effect
develop
met
relat
cardiovascular
complic
liu
wang
lam
xu
obes
individu
met
day
resveratrol
supplement
markedli
enhanc
energi
metabol
restor
insulin
sensit
glycaem
control
normalis
blood
pressur
plasma
lipid
profil
accompani
enhanc
mitochondri
function
skelet
muscl
result
increas
ampk
activ
express
nad
depend
deacetylas
resembl
calori
restrict
timmer
et
al
benefici
effect
resveratrol
appear
ampkdepend
mice
defici
metabol
sensor
longer
protect
metabol
derang
induc
high
fat
feed
despit
administr
resveratrol
um
et
al
context
copd
resveratrol
administr
mice
shown
allevi
haemophilu
influenzaeinduc
inflamm
airway
upregul
neg
regul
inflamm
short
andrew
matsuyama
lee
li
separ
studi
treatment
resveratrol
reduc
express
proinflammatori
cytokin
bronchoalveolar
lavag
fluid
balf
mice
expos
cigarett
smoke
along
resveratrol
treatment
also
attenu
cigarett
smokeinduc
fibrot
respons
mucu
hypersecret
lung
andrew
et
al
recent
studi
rat
also
confirm
efficaci
resveratrol
copd
benefici
effect
resveratrol
may
exert
via
axi
wang
li
li
miao
xiao
resveratrol
therapi
current
phase
clinic
trial
use
copd
patient
carmenstri
clinicaltrialsgov
identifi
overal
human
anim
studi
suggest
great
potenti
resveratrol
use
treat
met
possibl
copd
comorbid
fig
flavonoid
like
anthocyanin
shown
antioxid
stress
properti
guo
et
al
may
lower
ldl
cholesterol
metabol
paramet
dyslipidem
patient
qin
et
al
quercetin
anoth
flavonoid
shown
benefit
cardiovascular
health
lower
blood
pressur
plasma
oxid
ldl
concentr
overweight
subject
egert
et
al
natur
agent
genistein
triterpenoid
naringenin
curcumin
also
display
potent
vitro
activ
variou
aspect
met
xia
weng
howev
studi
need
verifi
benefit
copd
although
shortliv
freerad
like
hydroxylrad
peroxynitrit
extrem
reactiv
indiscrimin
point
would
attack
first
substrat
come
contact
result
impair
cellular
function
damag
bernardo
et
al
sinc
mitochondria
major
site
substrat
metabol
mean
also
major
sourc
ro
met
substrat
avail
excess
reason
mitochondriatarget
antioxid
compound
develop
examin
efficaci
anim
model
met
pharmacolog
mimet
sod
tempol
shown
effect
attenu
oxid
stress
restor
mitochondri
function
metabol
derang
ahm
shehata
abdelkad
khattab
mariappan
soorappan
haqu
sriramula
franci
likewis
administr
sod
mimet
anim
model
copd
also
appear
benefici
treatment
sod
mimet
rat
reduc
express
marker
oxid
stress
develop
emphysema
tuder
et
al
similar
copd
model
administr
differ
sod
mimet
aeol
found
reduc
airway
inflamm
cigarett
smoke
evidenc
signific
reduct
balf
cell
number
smith
et
al
line
gongora
et
al
gongora
et
al
demonstr
acut
ablat
via
gene
delet
result
sever
respiratori
distress
syndrom
resembl
advanc
copd
high
risk
mortal
gongora
et
al
contrari
overexpress
sod
attenu
airway
inflamm
respiratori
disord
follow
hyperoxia
turn
may
reduc
risk
mortal
highlight
excit
potenti
sod
therapeut
agent
metalloporphyrin
mntbap
anoth
sod
mimet
peroxynitrit
scaveng
properti
treatment
genet
obes
obob
mice
mntbap
improv
glucos
toler
insulin
sensit
maximum
effect
compar
anim
treat
antidiabet
agent
rosiglitazon
housti
rosen
lander
administr
mntbap
mice
shown
antagon
detriment
effect
cigarett
smoke
partli
inhibit
rhoarho
kinas
pathway
ultim
result
enhanc
clearanc
apoptot
cell
alveolar
macrophag
richen
et
al
coenzymeq
coq
vitaminlik
lipidsolubl
compon
mitochondri
electron
transport
chain
etc
due
role
electron
carrier
mitochondri
etc
coq
possess
potent
redox
properti
utilis
antioxid
lenaz
fato
formiggini
genova
contrast
vitamin
e
exogen
supplement
coq
readili
taken
cell
lead
mitochondri
local
enrich
saito
et
al
freerad
gener
along
line
diabet
anim
found
increas
oxid
stress
lipid
peroxid
reduc
level
coq
key
metabol
tissu
heart
liver
skelet
muscl
kucharska
braunova
ulicna
zlato
gvozdjakova
genet
obes
mice
treatment
coq
reduc
elev
plasma
lipid
profil
decreas
express
proinflammatori
cytokin
enhanc
express
antiinflammatori
insulinsensit
adipokin
adiponectin
carmona
et
al
studi
also
demonstr
addit
benefit
coq
therapi
neutralis
unwant
sideeffect
rosiglitazon
bodi
weight
adipos
diabet
rat
coq
supplement
markedli
increas
antioxid
enzym
activ
sod
catalas
glutathion
liver
diabet
rat
along
reduc
lipid
peroxid
modi
santani
goyal
bhatt
accompani
improv
hyperglycaemia
glucos
intoler
without
notic
chang
circul
insulin
level
modi
et
al
suggest
enhanc
insulin
sensit
potenti
treat
met
human
howev
month
coq
therapi
appar
benefit
glycaem
control
plasma
lipid
profil
overweight
diabet
subject
eriksson
forsen
mortensen
rohd
likewis
diabet
month
coq
therapi
result
improv
glycat
haemoglobin
mean
daili
blood
glucos
concentr
insulin
requir
number
hypoglycaem
episod
circulatori
cholesterol
concentr
compar
control
group
henriksen
et
al
also
lack
evid
substanti
role
cardiovascular
health
coq
supplement
unabl
amelior
hypertens
patient
met
bjelakov
nikolova
gluud
simonetti
gluud
young
et
al
appar
discrep
efficaci
coq
supplement
remain
unknown
howev
poor
water
solubl
lipophil
natur
coq
alam
rahman
might
constitut
poor
oral
bioavail
given
futur
studi
may
wish
explor
use
coq
adjunct
therapi
exist
medic
notion
support
find
addit
coq
regular
medic
improv
diastol
function
children
dilat
cardiomyopathi
kocharian
shabanian
rafielkhorgami
kiani
heidaribateni
limit
studi
assess
pulmonari
benefit
coq
supplement
eight
week
coq
administr
patient
copd
associ
significantli
elev
serum
coq
level
improv
hypoxemia
rest
subject
display
differ
oxygen
consumpt
exercis
howev
arteri
oxygen
satur
markedli
improv
lower
heart
rate
exercis
line
coq
administr
also
result
trend
enhanc
exercis
perform
lactat
product
concomitantli
suppress
fujimoto
kurihara
hirata
takeda
recent
studi
demonstr
dietari
supplement
creatin
coq
increas
lean
bodi
mass
exercis
toler
reduc
dyspnoea
exacerb
associ
copd
turn
improv
qualiti
life
patient
marinari
manigrasso
de
benedetto
data
suggest
coq
may
exert
favour
effect
cardiovascular
system
energi
metabol
patient
copd
via
attenu
hypoxemia
fig
attempt
overcom
limit
deriv
coq
develop
explor
mitoq
triphenylphosphoniumconjug
antioxid
improv
oral
bioavail
cellperm
sever
hundredfold
enhanc
local
affin
mitochondria
parent
molecul
coq
murphi
smith
mitoq
also
display
protect
effect
mitochondri
oxid
damag
effect
laboratori
rodent
rodriguezcuenca
et
al
rodent
oral
administr
mitoq
decreas
adipos
hypercholesterolemia
hypertriglyceridemia
associ
met
mitoq
administr
also
correct
hyperglycaemia
plasma
lipid
profil
rodent
minimis
dna
oxid
damag
multipl
organ
mercer
et
al
thu
far
use
mitoq
test
patient
parkinson
diseas
chronic
hepat
c
smith
murphi
report
advers
effect
suggest
potenti
suitabl
agent
alik
mitochondri
antioxid
mitotempol
prakash
pabelick
sieck
use
clinic
studi
treat
met
copd
addit
novel
mitochondriatarget
antioxid
also
identifi
includ
deriv
natur
product
berberin
palmatin
lyamzaev
et
al
well
synthet
antioxid
peptid
chen
liu
gao
zhuo
ge
exhibit
potent
radicalscaveng
properti
isol
mitochondria
human
cell
howev
use
context
met
copd
yet
explor
strong
associ
obes
pulmonari
health
prompt
therapeut
intervent
target
adipos
andor
restor
adipos
tissu
dysfunct
howev
exist
obes
paradox
rais
doubt
regard
appropri
target
obes
copd
patient
weight
loss
obes
copd
patient
one
hand
may
improv
cardiovascular
outcom
contrari
may
worsen
respiratori
outcom
even
increas
risk
mortal
cao
et
al
pisuny
vestbo
et
al
moreov
also
possibl
reduc
lung
volum
caus
obes
may
protect
hyperinfl
moder
sever
copd
turn
may
benefit
lung
function
followup
studi
involv
patient
stabl
copd
gold
overweight
obes
cohort
inde
better
lung
function
surviv
rate
normal
bmi
despit
significantli
higher
peak
work
rate
galesanu
et
al
howev
benefit
diminish
worsen
adjust
midthigh
muscl
crosssect
area
suggest
specul
benefit
greater
bmi
like
come
muscl
mass
rather
fat
recent
studi
orfano
et
al
also
demonstr
obes
induc
airway
smooth
muscl
hyperrespons
human
provid
anoth
pathogen
link
obes
copd
substanti
detriment
effect
obes
lung
function
find
provid
good
rational
target
obes
plausibl
therapeut
strategi
better
copd
outcom
howev
therapeut
approach
target
obes
problemat
weight
loss
intervent
particularli
elderli
group
result
loss
fat
mass
also
loss
skelet
muscl
mass
detriment
copd
context
passey
et
al
reason
clinician
face
dilemma
whether
recommend
weight
loss
obes
copd
patient
make
matter
wors
insuffici
evid
guid
manag
copd
patient
concurr
weight
issu
present
time
rais
urgent
call
intern
expert
research
area
schol
et
al
light
recent
studi
mcdonald
et
al
involv
obes
copd
patient
underw
strict
dietari
calori
restrict
regim
coupl
resist
exercis
train
result
clinic
signific
improv
bodi
mass
index
exercis
toler
health
statu
whilst
preserv
skelet
muscl
mass
find
studi
consist
result
obtain
obes
asthmat
cohort
modest
weight
loss
lead
signific
clinic
improv
health
statu
diseas
control
lv
xiao
although
assess
studi
reduct
excess
weight
gener
correl
significantli
lower
risk
comorbid
condit
aris
metabol
derang
pisuny
togeth
find
provid
proofofconcept
feasibl
benefit
weight
loss
intervent
obes
copd
patient
fig
futur
work
place
emphasi
treatment
intervent
would
preserv
andor
enhanc
skelet
muscl
mass
core
consider
manag
obes
copd
patient
nutrit
exercis
lifestyl
intervent
commonli
use
firstlin
treatment
obes
howev
lifestyl
intervent
alway
satisfactori
fact
recommend
adequ
weight
loss
lifestyl
intervent
achiev
within
month
pharmacotherapi
commenc
srivastava
apovian
import
note
primari
goal
pharmacotherapi
obes
improv
prevent
complic
aris
met
hypertens
dyslipidaemia
diabet
rather
weight
loss
per
se
srivastava
apovian
current
sever
food
drug
administr
fda
usa
approv
drug
use
longand
shortterm
manag
obes
number
sympathomimet
drug
phentermin
diethylpropion
approv
usa
shortterm
less
month
treatment
due
safeti
concern
man
pucci
finer
thu
appear
fit
ration
paradigm
treat
chronic
disord
copd
met
even
drug
approv
longterm
use
mean
weight
loss
attain
first
month
medic
altern
treatment
modal
consid
man
et
al
orlistat
potent
select
inhibitor
pancreat
lipas
requir
hydrolysi
dietari
fat
gastrointestin
tract
fatti
acid
monoacylglycerol
orlistat
approv
fda
usa
longterm
manag
obes
conjunct
diet
luca
kaplanmachli
mainli
attribut
neglig
system
absorpt
profil
zhi
melia
egger
joli
patel
doubleblind
prospect
studi
administr
orlistat
overweight
patient
result
signific
reduct
weight
mean
loss
kg
baselin
ie
treatment
torgerson
hauptman
boldrin
sjostrom
compar
lifestyl
intervent
alon
incid
type
diabet
also
found
significantli
reduc
cours
year
torgerson
et
al
moreov
orlistat
treatment
also
demonstr
benefici
effect
cardiovascular
risk
lower
blood
pressur
fast
glucos
level
well
serum
cholesterol
lipid
profil
broom
et
al
orlistat
use
overweightobes
patient
concurr
copd
must
proceed
caution
larg
obes
paradox
weight
loss
period
month
shown
profound
neg
impact
copd
prognosi
qureshi
et
al
shavel
paculdo
kush
mannino
strauss
precaut
imped
use
orlistat
similar
weight
loss
agent
popul
therapeut
intervent
coupl
dietari
exercis
rehabilit
maintain
lean
bodi
mass
meanwhil
sign
unintent
weight
loss
andor
side
effect
close
monitor
promptli
act
upon
accordingli
lorcaserin
anoth
fdaapprov
agent
use
longterm
manag
obes
hypothalamu
lorcaserin
activ
serotonin
receptor
lead
suppress
appetit
reduc
calor
intak
without
direct
impact
energi
expenditur
halford
harrold
boyland
lawton
blundel
clinic
administr
lorcaserin
demonstr
effect
weight
loss
along
favour
safeti
profil
sign
heartvalv
problem
unlik
receptor
agonist
fidler
et
al
oneil
et
al
smith
et
al
administr
lorcaserin
obes
diabet
subject
exert
signific
improv
glycaem
control
evidenc
reduct
mean
level
fast
blood
glucos
oneil
et
al
far
experiment
evid
clinic
data
suggest
benefit
lorcaserin
administr
respiratori
disord
given
preclin
clinic
studi
indic
lorcaserin
welltoler
associ
cardiac
valvulopathi
pulmonari
hypertens
redman
ravussin
possibl
copd
patient
weight
control
issu
may
benefit
lorcaserin
therapi
especi
use
conjunct
lifestyl
intervent
noteworthi
similar
weight
loss
precaut
also
appli
use
lorcaserin
sign
serotonin
syndrom
also
close
monitor
use
serotonerg
medic
halford
et
al
phentermin
anoth
sympathomimet
drug
stimul
releas
synapt
noradrenalin
dopamin
serotonin
releas
lead
appetitesuppress
man
et
al
describ
phentermin
alon
recommend
shortterm
use
howev
combin
topiram
phentermin
suitabl
longterm
use
allison
et
al
gadd
et
al
synergist
effect
phentermin
extendedreleas
topiram
market
qnexaqsivaqsymia
allow
dose
reduct
drug
thu
less
toxic
without
loss
efficaci
gadd
et
al
topiram
anticonvuls
drug
origin
use
epilept
patient
weight
lossinduc
properti
accident
discov
astrup
toubro
phenterminetopiram
therapi
week
report
welltoler
result
dosedepend
weight
loss
baselin
allison
et
al
gadd
et
al
weight
loss
associ
variou
improv
metabol
paramet
includ
systol
diastol
blood
pressur
fast
glucos
triglycerid
total
cholesterol
ldl
hdl
allison
et
al
despit
demonstr
safeti
efficaci
treat
obes
metabol
derang
studi
todat
examin
effect
phentermin
topiram
respiratori
diseas
expos
need
research
area
light
rel
lack
prospect
novel
antiobes
therapi
high
attrit
rate
associ
drug
develop
chan
ye
recent
research
clinician
begun
turn
drug
repurpos
strategi
attempt
broaden
therapeut
option
shih
zhang
aronov
glucagonlik
base
therapi
repres
one
best
exampl
antiobes
therapi
deriv
strategi
belong
group
hormon
call
incretin
secret
enteroendocrin
cell
gut
bloodstream
shortli
follow
food
consumpt
respons
enhanc
insulin
secretori
respons
pancrea
product
eg
glucos
within
nutrient
food
garber
addit
recent
research
indic
mediat
satiat
act
peripher
central
pathway
holst
appetitesuppress
properti
may
therapeut
applic
fight
obes
two
class
base
therapi
develop
agonist
exenatid
liraglutid
exhibit
increas
resist
dipeptidyl
peptidas
degrad
thu
provid
pharmacolog
level
ii
inhibitor
sitagliptin
vildagliptin
saxagliptin
reduc
endogen
degrad
therebi
provid
physiolog
level
garber
belong
famili
b
subclass
g
proteincoupl
receptor
gpcr
activ
receptor
result
amplif
intracellular
signal
via
protein
kinas
pka
turn
drive
express
biosynthesi
secret
insulin
pancreat
glucosedepend
manner
drucker
philipp
mojsov
chick
haben
agonist
welltoler
demonstr
efficaci
monotherapi
combinationtherapi
exenatid
defronzo
et
al
liraglutid
garber
et
al
zinman
et
al
demonstr
moder
signific
weight
loss
especi
administ
concert
insulinsensit
agent
like
metformin
minim
advers
effect
hypoglycaemia
agonist
effect
improv
glycaem
control
obes
patient
concurr
diabet
evidenc
reduct
mean
level
defronzo
et
al
garber
et
al
zinman
et
al
experiment
mice
model
aecopd
induc
inhal
ovalbumin
lipopolysaccharid
administr
agonist
significantli
improv
pulmonari
function
reduc
sever
exacerb
enhanc
surviv
rate
independ
chang
mrna
express
proinflammatori
cytokin
surfact
protein
lung
vibi
et
al
moreov
function
express
lung
tissu
romaniperez
et
al
vibi
et
al
appear
import
role
regul
surfactantprotein
product
lung
develop
experiment
rat
model
romaniperez
et
al
whole
evid
indic
agonist
appear
safe
effect
obes
variou
paramet
metabol
derang
patient
neg
effect
cardiovascular
risk
patient
filippato
panagiotopoul
elisaf
thu
agonist
appear
favour
safeti
profil
ongo
trial
assess
effect
pulmonari
compon
well
mechan
action
contrari
effect
inhibitor
weight
loss
appear
variabl
controversi
metaanalysi
clinic
studi
verifi
efficaci
three
inhibitor
weight
loss
insignific
amori
lau
pitta
despit
neutral
effect
bodi
weight
three
inhibitor
display
similar
efficaci
glycaem
control
reflect
reduct
level
along
good
safeti
profil
patient
toler
amori
et
al
noteworthi
studi
also
suggest
inhibitor
slightli
less
effect
sulfonylurea
effect
metformin
thiazolidinedion
standard
drug
treat
diabet
term
reduc
blood
glucos
addit
glycaem
control
inhibitor
also
appear
exert
benefici
effect
vasculatur
diabet
patient
concurr
coronari
heart
diseas
sitagliptin
treatment
improv
heart
function
coronari
arteri
perfus
read
khan
heck
hool
dutka
separ
studi
show
sitagliptin
treatment
result
moder
signific
reduct
diastol
blood
pressur
nondiabet
hypertens
patient
mistri
et
al
final
week
vildagliptin
administr
drugnaiv
patient
type
diabet
associ
improv
postprandi
plasma
triglycerid
apolipoprotein
triglyceriderich
lipoprotein
particl
metabol
follow
fatrich
meal
matikainen
et
al
similar
effect
vildagliptin
postprandi
lipid
mobil
oxid
report
recent
studi
like
mediat
via
sympathet
activ
rather
direct
effect
metabol
statu
boschmann
et
al
unlik
agonist
far
experiment
clinic
studi
examin
pulmonari
aspect
inhibitor
therapi
howev
noteworthi
inhibitor
therapi
shown
coincid
increas
risk
upper
respiratori
tract
infect
amori
et
al
willemen
et
al
may
limit
experiment
clinic
use
copd
evid
previou
weight
loss
research
indic
life
style
rehabilit
pharmacotherapi
often
ineffect
patient
sever
obes
issu
lose
enough
weight
improv
health
qualiti
life
long
term
pisuny
meanwhil
grow
bodi
evid
indic
bariatr
surgeri
effect
attain
sustain
weight
control
improv
comorbid
prolong
surviv
sjostrom
et
al
addit
revers
obes
bariatr
surgeri
shown
improv
paramet
met
includ
abnorm
plasma
lipid
cholesterol
profil
elev
blood
pressur
fast
glucos
batsi
et
al
turn
may
reduc
cardiovascular
risk
batsi
et
al
recent
studi
conduct
obes
patient
copd
us
found
bariatr
surgeri
remark
reduc
incid
emerg
visit
hospit
relat
aecopd
patient
concurr
obes
goto
tsugawa
faridi
camargo
jr
hasegawa
obes
profoundli
imping
respiratori
mechan
contribut
manifest
deterior
symptom
possibl
surgic
weight
loss
may
contribut
allevi
copd
symptom
lower
system
inflamm
fig
line
reduc
system
crp
level
observ
morbidli
obes
patient
follow
surgic
weight
loss
moreov
system
appear
solubl
intercellular
adhes
key
mediat
atherosclerot
plaqu
format
also
found
dramat
reduc
follow
surgic
weight
loss
orea
soler
et
al
may
explain
associ
cardiovascular
benefit
natur
product
deriv
plant
microb
anim
invalu
sourc
molecular
divers
drug
discoveri
greatli
contribut
identif
new
drug
drug
deriv
chan
ye
li
vedera
use
fish
oil
exampl
enrich
fatti
acid
name
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
calder
experiment
evid
demonstr
fatti
acid
restor
metabol
function
adipos
tissu
promot
oxid
metabol
via
mitochondri
biogenesi
fatti
acid
oxid
flach
et
al
epa
dha
promot
glucos
util
insulin
sensit
key
metabol
tissu
includ
liver
skelet
muscl
adipos
tissu
activ
peroxisom
proliferatoractiv
receptor
gamma
ampk
neschen
et
al
oh
et
al
storlien
et
al
storlien
et
al
moreov
epa
dha
also
appear
suppress
product
proinflammatori
chemokin
cytokin
increas
express
antiinflammatori
cytokin
adipokin
adiponectin
adipos
tissu
turn
may
reduc
inflamm
kalupahana
claycomb
moustaidmoussa
oh
et
al
although
yet
fulli
elucid
mechan
underli
antiinflammatori
action
fatti
acid
may
relat
abil
alter
cellular
membran
phospholipid
composit
disrupt
lipid
raft
suppress
proinflammatori
transcript
factor
reduc
transcript
proinflammatori
gene
activ
antiinflammatori
transcript
factor
inhibit
signal
via
bind
g
protein
coupl
receptor
adipocyt
macrophag
hepat
stellat
cell
calder
disappointingli
data
clinic
trial
support
link
either
epa
dha
restor
insulin
sensit
metaanalysi
random
control
trial
rct
particip
conclud
fatti
acid
consumpt
affect
insulin
sensit
akinkuoli
ngwa
meig
djouss
anoth
systemat
review
involv
rct
least
month
continu
administr
fatti
acid
also
found
clear
effect
variou
risk
factor
met
despit
signific
improv
blood
pressur
lipid
profil
advers
effect
report
lopezhuerta
note
data
doserespons
studi
healthi
subject
demonstr
exist
threshold
antiinflammatori
effect
epa
ree
et
al
impli
daili
intak
fatti
acid
must
exceed
certain
level
order
exert
health
benefit
summari
human
studi
larg
fail
recapitul
protect
effect
epa
dha
glucos
metabol
insulin
sensit
observ
rodent
besid
obviou
interspeci
genet
phenotyp
differ
also
noteworthi
major
intervent
studi
rodent
conduct
parallel
diseas
develop
prevent
protocol
wherea
intervent
studi
human
typic
administ
establish
diseas
revers
protocol
henc
clinic
trial
properli
take
account
aforement
discrep
need
conclus
system
use
fatti
acid
met
made
laboratori
evid
suggest
fatti
acid
also
exert
benefici
antiinflammatori
effect
arachidon
acid
metabol
pathway
downstream
balanc
eicosanoid
includ
prostaglandin
leukotrien
may
influenc
neutrophil
recruit
bronchoconstrict
calder
moreov
fish
intak
rich
sourc
fatti
acid
children
associ
reduc
wheez
asthma
major
epidemiolog
cohort
studi
wendel
baffi
holguin
current
ancillari
studi
ongo
subset
particip
vitamin
hypertens
trial
vital
hypertens
aim
examin
whether
fatti
acid
supplement
gday
may
improv
respiratori
symptom
reduc
risk
lung
infect
declin
pulmonari
function
subcohort
vitalhypertens
compos
particip
gender
year
older
continent
us
locat
subject
random
lung
function
test
accept
qualiti
among
mild
moder
copd
display
obstruct
spirometri
evidenc
fev
b
normal
moreov
mean
bmi
obes
suggest
subject
enter
studi
either
overweight
borderlin
obes
gold
et
al
outcom
trial
would
undoubtedli
advanc
understand
regard
therapeut
potenti
fatti
acid
copd
plant
tradit
tremend
sourc
natur
product
benefici
effect
sever
type
diseas
includ
met
copd
use
ginseng
date
back
five
thousand
year
ago
legendari
emperor
shennong
ancient
china
report
literatur
first
classifi
hundr
medicin
poison
herb
give
rise
bedrock
oldest
pharmacopoeia
world
yun
thirteen
speci
ginseng
identifi
panax
ginseng
korean
ginseng
panax
quinquefoliu
american
ginseng
commonli
use
baeg
administr
ginseng
demonstr
number
posit
effect
glucos
lipid
metabol
human
eight
weekor
administr
heatprocess
panax
ginseng
decreas
fast
blood
glucos
level
increas
serum
insulin
glucos
toler
streptozotocininduc
diabet
mice
jang
et
al
highfructos
fed
rat
panax
ginseng
administr
eight
week
significantli
reduc
increment
bodi
weight
adipos
associ
reduc
hyperlipidemia
hypertens
togeth
amelior
endotheli
dysfunct
mark
upregul
glucos
transport
type
muscl
suggest
enhanc
insulin
sensit
kho
et
al
similar
result
also
obtain
obob
mice
week
panax
ginseng
administr
drink
water
cheon
kim
kim
moreov
panax
ginseng
also
appear
enhanc
islet
function
attenu
cytokineinduc
apoptosi
kim
et
al
may
explain
benefici
effect
glucos
metabol
luo
dong
liu
zhou
metabol
benefit
panax
ginseng
may
extend
cardiovasculatur
longterm
consumpt
ginseng
extract
shown
reduc
suscept
acut
ischemia
reperfus
heart
injuri
rat
upregul
action
sirtuin
luo
et
al
clinic
set
panax
ginseng
shown
exert
posit
effect
glucos
metabol
reflect
improv
glucos
toler
shergi
zhang
zhou
xue
metaanalysi
random
control
trial
moder
durat
day
assess
glycaem
effect
ginseng
diabet
patient
found
ginseng
modestli
yet
significantli
improv
fast
blood
glucos
peopl
without
diabet
shishtar
et
al
must
note
studi
short
durat
particip
includ
also
rel
stabl
glycaem
control
median
trial
median
trial
henc
larger
longer
durat
random
control
trial
use
standard
prepar
need
valid
ginseng
antidiabet
metabol
efficaci
addit
glucos
metabol
panax
ginseng
also
appear
modul
immun
respons
may
import
implic
chronic
inflammatori
diseas
copd
shergi
et
al
deliveri
panax
ginseng
form
mg
patient
chronic
bronchiti
demonstr
enhanc
bacteri
clearanc
rate
follow
acut
attack
compar
receiv
antibacteri
alon
scaglion
cogo
cocuzza
arcidiacono
beretta
scaglion
weiser
alessandria
similar
note
panax
ginseng
panax
quinquefoliu
also
shown
offer
protect
upper
respiratori
tract
infect
rhinoviru
coronaviru
random
doubleblind
placebo
control
trial
involv
healthi
volunt
lee
et
al
administr
mg
patient
moder
sever
copd
week
associ
increas
fev
fvc
well
vo
correl
exercis
capac
gross
et
al
although
improv
gradual
subsid
week
posttreat
piec
clinic
evid
provid
proofofconcept
therapeut
use
panax
ginseng
copd
line
systemat
review
also
conclud
promis
benefit
panax
ginseng
improv
fev
qualiti
life
patient
evidenc
st
georg
respiratori
questionnair
compar
treatment
administ
combin
pharmacotherapi
compar
pharmacotherapi
alon
wu
et
al
recent
conduct
pilot
studi
base
fullscal
week
trial
protocol
wu
et
al
compar
panax
ginseng
placebo
treat
moder
sever
copd
feasibl
studi
involv
nine
particip
copd
found
p
ginseng
twice
daili
well
toler
advers
event
report
base
success
fullscal
trial
approv
regist
anzctr
actrn
implement
guangdong
provinci
hospit
chines
medicin
china
overal
use
natur
product
ginseng
appear
welltoler
healthi
subject
patient
metaanalysi
result
indic
addit
natur
product
routin
pharmacotherapi
may
produc
addit
benefit
term
decreas
bode
index
increas
walk
distanc
stabl
copd
patient
use
six
month
chen
et
al
anoth
natur
product
proven
effect
treat
variou
diseas
codonopsi
speci
dang
shen
belong
campanulacea
famili
root
extract
codonopsi
speci
demonstr
possess
pharmacolog
efficaci
antioxid
antitumor
antimicrobi
immuneboost
properti
luo
et
al
pharmacolog
wang
ng
yeung
xu
efficaci
codonopsi
root
like
due
attribut
enrich
constitu
includ
polysaccharid
saponin
alkaloid
phytosteroid
li
xu
han
wu
yongxu
jicheng
codonopsi
root
commonli
use
combin
natur
product
formul
treat
stabl
copd
metaanalysi
random
control
trial
found
clinic
therapi
codonopsi
root
exert
number
posit
effect
pulmonari
function
minim
advers
event
copd
patient
codonopsi
root
therapi
improv
fev
walk
distanc
compar
convent
pharmacotherapi
bronchodil
mucolyt
patient
also
reduc
exacerb
better
qualiti
life
reflect
st
georg
respiratori
questionnair
compar
placebo
systemat
review
highlight
suffici
evid
support
routin
use
codonopsi
root
standard
clinic
therapi
metabol
diseas
context
administr
codonopsi
root
extract
fructosef
rat
significantli
attenu
weight
gain
fast
hyperinsulinemia
accompani
improv
glucos
toler
rat
codonopsi
root
extract
also
protect
oxid
damag
result
lipid
peroxid
like
due
improv
antioxid
enzym
activ
includ
superoxid
dismutas
glutathion
peroxidas
glutathion
reductas
liver
chen
et
al
moreov
nonobes
diabet
rat
consumpt
codonopsi
root
extract
effect
reduc
serum
glucos
level
urinari
appear
glucos
compar
control
treat
rat
also
display
greater
glucos
infus
rate
togeth
hyperinsulinem
euglycaem
clamp
lower
hepat
glucos
output
basal
hyperinsulinem
condit
indic
restor
insulin
sensit
jeong
kang
kim
park
likewis
oral
supplement
codonopsi
root
extract
result
lower
fast
blood
glucos
insulin
highfat
diet
induc
obes
mice
associ
improv
serum
profil
triglycerid
total
cholesterol
ldl
compar
highfat
diet
fed
mice
addit
supplement
also
exert
benefit
adipos
liver
function
obes
mice
lee
et
al
overal
experiment
evid
indic
therapeut
potenti
codonopsi
root
treat
met
may
exert
via
obesitydepend
independ
mechan
howev
efficaci
treat
met
human
still
await
clinic
verif
review
medic
record
australian
clinic
reveal
acupunctur
frequent
form
complementari
medicin
use
respiratori
disord
nik
nabil
et
al
systemat
review
rct
examin
benefit
acupunctur
relat
therapi
treatment
copd
reveal
acupunctur
therapi
improv
healthrel
qualiti
life
patient
mild
sever
form
copd
coyl
et
al
despit
associ
improv
st
georg
respiratori
questionnair
score
medic
research
council
dyspnoea
scale
dyspnoea
visual
analogu
scale
greater
walk
distanc
compar
placebo
control
acupunctur
therapi
reportedli
addit
effect
pulmonari
function
compar
either
placebo
pharmacotherapi
although
directli
benefit
pulmonari
function
emerg
evid
suggest
earacupunctureacupressur
may
help
individu
maintain
smoke
cessat
warrant
investig
metabol
context
acupunctur
intervent
recent
explor
martinez
peplow
author
conclud
electroacupunctur
modern
form
acupunctur
low
intens
low
frequenc
may
amelior
insulin
resist
enhanc
insulin
sensit
experiment
model
human
insulinresist
condit
thu
highlight
potenti
use
monotherapi
addon
therapi
dietexercis
intervent
treat
chronic
diseas
like
copd
met
fig
grow
bodi
research
indic
correl
link
met
pulmonari
dysfunct
copd
correl
impli
compon
met
particularli
hyperglycaemia
give
rise
pulmonari
function
impair
copd
vice
versa
regardless
direct
drive
concurr
exist
met
copd
amplifi
individu
risk
cardiovascular
comorbid
major
caus
mortal
patient
although
causal
relationship
underli
mechan
develop
two
chronic
diseas
intertwin
natur
appar
major
risk
factor
onset
copd
cigarett
smoke
met
obes
system
inflamm
oxid
stress
emerg
import
link
connect
copd
met
extrapulmonari
patholog
cvd
copd
system
inflamm
may
result
spill
lungderiv
proinflammatori
mediat
includ
white
blood
cell
crp
fibrinogen
copd
patient
weight
gain
issu
adipos
tissu
may
also
releas
panel
adipokin
leptin
may
potenti
spill
inflamm
lung
parallel
loss
skelet
muscl
mass
associ
physic
inact
may
negat
homeostat
effect
myokin
exacerb
system
inflamm
alter
oxid
balanc
copd
may
deplet
endogen
antioxid
defenc
lead
oxid
cellular
compon
molecul
within
lung
adipos
tissu
skelet
muscl
sustain
role
system
inflamm
polypharmaci
major
issu
commonli
encount
copd
patient
comorbid
syndrom
treat
isol
franssen
spruit
wouter
mean
risk
advers
event
due
combin
drug
increas
complianc
may
becom
difficult
particularli
elderlyfrail
group
patient
therefor
identifi
converg
mechan
treat
lungsystem
inflamm
comorbid
met
concurr
key
focu
futur
therapeut
intervent
declar
present
manuscript
publish
consider
public
elsewher
author
declar
conflict
interest
